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2 Abbreviations 
Ab   antibody 
Ag   antigen 
ADCC   antibody-dependent cell-mediated cytotoxicity 
APC   antigen-presenting cell 
BCR   B cell receptor 
CD   cluster of differentiation 
CSR   class switch recombination 
CTL   cytotoxic T lymphocyte 
CTLA-4  cytotoxic T lymphocyte-associated antigen-4 
DC   dendritic cell 
DNA   deoxyribose nucleic acid 
DTH   delayed type hypersensitivity 
EDTA   ethylenediaminetetraacetic acid 
GITR   glucocorticoid-induced tumor necrosis factor receptor 
HDM   house dust mite 
HR1   histamine receptor 1 
HR2   histamine receptor 2 
HR3   histamine receptor 3 
HR4   histamine receptor 4 
IFN-γ   interferon-γ 
Ig   immunoglobulin 
IL   interleukin 
IPEX immune dysregulation, polyendocrinopathy, enteropathy X-
linked syndrome 
LC Langerhans’ cell 
LPS   lipopolysacharide 
MHC   major histocompatibility complex 
mRNA   messenger ribonucleic acid 
NFκB   nuclear factor κB 
NK   natural killer 
PAMP   pathogen-associated molecular patterns 
PBMC   peripheral blood mononuclear cells 
PD-1   programmed death-1 
SHM   somatic hypermutation  
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SIT   specific immunotherapy 
TCR   T cell receptor 
TGF-β   transforming growth factor-β 
TLR   Toll-like receptor 
Th   T helper cell 
Tr1   type 1 regulatory T cell 
Treg   T regulatory 
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3 Summary 
Activation of the immune system and production of immunoglobulin (Ig) E against 
innocuous environmental antigens leads to allergic diseases. The non-inflammatory 
antibody isotypes IgG4 and IgA play an important role in neutralisation and 
subsequent clearance of antigens. It is still not clearly known why some people 
develop allergic reactions and others do not, but the balance between allergen-
specific T helper (Th) 2 cells and the IL-10-secreting T regulatory type 1 (Tr1) cells 
seems to be very important. Whereas healthy individuals have a higher frequency of 
allergen-specific Tr1 cells, allergen-specific Th2 cells are more prevalent in allergic 
people. Tr1 cells show a suppressive effect on T cell activation, are induced in the 
periphery during specific immunotherapy (SIT) and therefore are very important for 
induction and maintenance of peripheral tolerance. Another subset of regulatory T 
(Treg) cells comprises CD4+CD25+FoxP3+ T cells, which have similar features as Tr1 
cells, they are called natural Treg cells since they originate in the thymus, however, 
they can also be generated in the periphery. 
Since it is well known that B cells need Th1- or Th2 cell-help to generate Igs, 
we investigated whether regulatory T cells also influence Ig production. We showed 
that both IL-10-secreting Tr1 and CD4+CD25+ Treg cells suppress IgE, but induce 
IgG4 production, however, production of IgA was not affected. Very interestingly, IgA 
induction was stongly dependent on activation of the innate immune system, 
specially TLR7 or TLR9 stimulation on B cells, and did not require T cell help. This 
could endow the human system with a very fast immune response to combat 
invading pathogens. 
For better understanding the mechanisms of T cell tolerance, we investigated 
the immune response of several non-allergic beekeepers, which received high doses 
of bee venom via natural bee stings during their occupation. We could observe that 
continuous exposure to high doses of bee venom antigens leads to a clonal switch of 
venom antigen-specific Th1 and Th2 cells towards IL-10-secreting Tr1 cells. These 
high numbers of antigen-specific Tr1 cells persisted as long as antigen was present, 
however, they returned to initial levels two to three months after the last bee sting. 
Furthermore, histamine receptor 2 (HR2), which is predominantly expressed on 
effector Th2 cells, is upregulated and directly suppresses activated Th2 cells and 
induces IL-10 production by DCs, Treg  and Th2 cells. 
We conclude that Tr1 cells, which are increased during SIT, as well as 
CD4+CD25+ Treg cells contribute to the control of allergen-specific immune 
Summary
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responses in several ways: I) Suppression of antigen-presenting cells that support 
the generation of effector Th2 and Th1 cells; II) suppression of Th2 and Th1 cells; III) 
suppression of mast cells, basophils and eosinophils; IV) interaction with resident 
tissue cells and remodeling, and, as shown in this study, V) induction of the non-
inflammatory antibody isotype IgG4 and suppession of the inflammatory antibody 
isotype IgE. In addition, we could gain more insight into the mechanisms of 
peripheral tolerance, which is crucial for a healthy immune response.  
Induction of Treg cells or the increase of their suppressive capacity by drugs, 
cytokines or costimulatory molecules is an important target not only for the treatment 
of allergy and asthma, but also for transplantation and autoimmunity. 
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4 Zusammenfassung 
Die Aktivierung des Immunsystems und die damit verbundene Bildung von 
Immunglobulin (Ig) E gegen normalerweise harmlose Umweltantigene führt zu 
allergischen Erkrankungen. Die Immunglobuline IgG4 und IgA mit ihren anti-
inflammatorischen Eigenschaften spielen eine wichtige Rolle bei der Neutralisierung 
und Beseitigung eines Antigens. Der Grund, warum ein Antigen in einigen Personen 
eine allergische Reaktion auslöst und in anderen nicht, ist noch nicht genau bekannt. 
Man weiss jedoch, dass das Gleichgewicht zwischen allergen-spezifischen T-Helfer 
2-Zellen (Th2) und den IL-10-sekretierenden regulatorischen T-Zellen (Tr1) 
entscheidend ist. Gesunde Personen haben mehr allergen-spezifische Tr1-Zellen, 
Allergiker hingegen besitzen mehr allergen-spezifische Th2-Zellen. Tr1-Zellen 
unterdrücken aktivierte Th-Zellen und werden während der allergen-spezifischen 
Immuntherapie (SIT) gebildet. Das zeigt, dass sie sehr wichtig für die Induktion und 
Erhaltung der peripheren Toleranz sind. Die CD4+CD25+FoxP3+ T-Zellen gehören 
ebenfalls zu den regulatorischen T (Treg) Zellen, bilden jedoch eine eigenständige 
Population. Sie besitzen ähnliche Eigenschaften wie Tr1-Zellen, werden jedoch 
natürliche Tregs genannt weil sie im Thymus gebildet werden, aber sie können auch 
in der Peripherie entstehen. 
Da seit langem bekannt ist, dass B Zellen zunächst durch T-Helfer 1 (Th1)- 
oder Th2-Zellen aktiviert werden müssen um Antikörper zu produzieren, 
untersuchten wir, ob auch Tregs einen Einfluss auf die Antikörperbildung haben. Wir 
zeigten, dass sowohl die Tr1-Zellen als auch die CD4+CD25+ Treg-Zellen die IgE 
Produktion unterdrückten, die IgG4 Bildung jedoch erhöhten, die IgA Produktion 
hingegen war nicht beeinflusst. Interessanterweise wurde IgA durch die Aktivierung 
des angeborenen Immunsystems induziert. Dies geschah durch die Stimulierung der 
Toll-like Rezeptoren (TLR) 7 und 9 auf den B Zellen und ohne Hilfe der T-Zellen. 
Dieser Abwehrmechanismus könnte dem menschlichen Körper dazu dienen, 
eindringende Krankheitserreger schnell zu beseitigen. 
Um die Mechanismen der T-Zelltoleranz besser zu verstehen, untersuchten 
wir die Immunantwort bei nicht-allergischen Imkern, die durch Bienenstiche hohe 
Dosen Bienengift erhalten hatten. Anhaltende hohe Bienengiftkonzentrationen hatten 
einen klonalen Wechsel von antigen-spezifischen Th1- und Th2-Zellen hin zu IL-10-
sekretierenden Tr1-Zellen zur Folge. Die erhöhte Anzahl antigen-spezifischer Tr1-
Zellen blieb bestehen, solange das Antigen präsent war. Zwei bis drei Monate nach 
dem letzten Bienenstich ging die Anzahl der Tr1-Zellen jedoch wieder auf 
Zusammenfassung
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anfängliche Werte zurück. Ausserdem wurde der Histaminrezeptor (HR) 2, der vor 
allem auf den Th2-Zellen exprimiert wird, hochreguliert. Dies führte zur Hemmung 
aktivierter Th2-Zellen und zur IL-10 Produktion durch dendritische Zellen, Tregs und 
Th2-Zellen.  
Wir kommen zum Schluss, dass sowohl Tr1-Zellen, welche während der SIT 
gebildet werden, als auch die CD4+CD25+ Treg-Zellen eine wichtige Rolle bei der 
Kontrolle der allergen-spezifischen Immunantwort spielen und zwar indem sie: I) 
Antigen-präsentierende Zellen, welche für die Generierung der Th1- und Th2-Zellen 
verantwortlich sind, unterdrücken; II) Th2- und Th1-Zellen unterdrücken; III) 
Mastzellen, Basophile und Eosinophile unterdrücken; IV) mit residenten 
Gewebszellen und dem Remodelling interagieren und, wie wir hier zeigen konnten, 
V) die nicht-inflammatorischen IgG4 Antikörper induzieren, die inflammatorischen IgE 
Antikörper jedoch supprimieren. Zudem konnten wir einen tieferen Einblick in die 
Mechanismen der peripheren Toleranz gewinnen, die für eine normale 
Immunantwort äusserst wichtig ist. 
Induktion der Treg-Zellen oder die Verstärkung ihrer suppressiven Kapazität 
durch Medikamente, Zytokine oder co-stimulatorische Moleküle wäre nicht nur für die 
Behandlung von Allergien und Asthma von Vorteil, sondern könnte auch bei 
Transplantationen und Autoimmunkrankheiten eingesetzt werden.  
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5 Introduction 
 
5.1  History 
In 1906, the Austrian paediatrician Clemens von Pirquet observed in his patients an 
“altered reactivity” when they were exposed to different environmental substances 
and therefore, he created the term “allergy” (Greek allos, other; ergon, 
energy/response). Later, these environmental substances were called  “allergens”. 
Allergy is a tissue-damaging immune response and involves both a foreign 
substance (allergen) and a genetic susceptibility. Affected individuals can produce a 
specific class of antibody, namely IgE, which is responsible for the majority of 
manifestations seen in patients with allergic diseases.  
In 1890, Emil von Behring and Shibasaburo Kitasato discovered antibody 
activity against diphtheria and tetanus toxins. Behring and Kitasato proposed that a 
mediator in serum could react with a foreign antigen (1). Seven years later, Behring 
and Kitasato described a "lock-and-key" interaction between receptors and specific 
toxins on the surface of cells and hypothesized this binding as the trigger for the 
antibody production (2). Almroth Wright suggested in 1904, that soluble antibodies 
could label bacteria by coating them, and therefore render them susceptible for 
phagocytosis and killing; e termed this process opsonization (3). 
In the 1920s, Michael Heidelberger and Oswald Avery showed that antigens 
could be precipitated by antibodies. They also discovered that antibodies were made 
of protein (4). The lock-and key theory proposed by Ehrlich was confirmed by Linus 
Pauling in the 1940s (5). In 1948, Astrid Fagreaus observed that plasma cells could 
produce antibodies (6) and Gerald Edelman and Joseph Gally discovered the 
antibody light chain in the early 1960s (7). Thereafter, Edelman could show that 
antibodies are composed of disulphide bond-linked heavy and light chains. Around 
the same time, antibody-binding (Fab) and antibody tail (Fc) regions of IgG were 
characterized by Rodney Porter (8). Together, these scientists suggested the 
structure and complete amino acid sequence of IgG, and were awarded the Nobel 
prize in Physiology and Medicine in 1972 (8). Also other immunoglobulin isotypes 
were discovered in the 1960s: Thomas Tomasi found secretory antibody (IgA) (9), 
Rowe and Fahey identified IgD (10), and IgE was discovered by Kikishige and Teruki 
Ishizaka (11).  
Introduction
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In 1963, Coombs and Gell established a classification of hypersensitivity 
reactions upon differences in the mechanisms, cells, and mediator molecules 
involved. Three types of hypersensitivity belong to the humoral branch and are 
mediated by antibody or antigen-antibody complexes. A forth type is part of the cell-
mediated branch (Table 1). 
 
Table 1. Hypersensitivity responses 
 Type I Type II Type III Type IV 
Immune 
mechanisms 
IgE-mediated 
(Immediate 
hypersensitivity) 
IgM-, IgG-mediated  Immune complex-
mediated (IgM, IgG) 
T cell-mediated 
Antigen Soluble antigen Cell- or extracellular 
matrix-associated 
antigen 
Soluble antigen Soluble or cell-
associated antigen 
Effector 
mechanisms 
Crosslinking of IgE 
bound on mast cells 
and basophils and 
subsequent 
degranulation 
Opsonization and 
phagocytosis of 
cells, complement 
activation or 
antibody-dependent 
cell-mediated 
cytotoxicity (ADCC) 
Ag-Ab complexes 
deposited in various 
tissues induce 
complement 
activation and 
infiltration of 
neutrophils 
Sensitized Th1 cells 
release cytokines 
that activate 
macrophages or 
CTLs which mediate 
cell killing 
Clinical 
manifestations 
Systemic 
anaphylaxis, allergic 
rhinitis, asthma, food 
allergies, eczema, 
hives 
Blood transfusion 
reactions, some 
drug allergies (e.g. 
penicillin), tissue 
injury 
Arthus reaction, 
serum sickness, 
systhemic lupus 
erythematosus, 
vasculitis 
Contact dermatitis, 
graft rejection 
Time Within minutes Takes hours to a 
day 
Takes hours, days 
or weeks 
Takes two to three 
days to develop 
Adapted from Abbas and Lichtman, Cellular and Molecular Immunology. Fifth ed. 
Philadelphia: Saunders 2003, Goldsby et al., Immunology. Fifth ed. New York: Freeman 
2003. 
 
 
5.2  The adaptive immune system 
The immune system is divided into the innate immunity, which is less specific and 
into the adaptive immunity, which is very specific. The first line of defense against 
infection is provided by the innate immunity. The adaptive immunity develops as a 
response and adapts to the infection, and is characterized by outstanding specificity 
for distinct molecules and an ability to remember and respond more efficiently to 
repeated exposures to the same microbe. Furthermore, it has an extraordinary 
capacity to distinguish among very closely related microbes and molecules. There 
are two types of adaptive immune responses, called humoral immunity and cell-
Introduction
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mediated immunity. Humoral immunity is performed by antibodies that are produced 
by B cells. Cell-mediated immunity, which is performed by T cells, is responsible for 
the destruction of microbes that reside in phagocytes or for the killing of infected 
cells.  
 
5.2.1 T helper cells 
The generation of allergen-specific CD4+ T helper cells (Th) is the initial event which 
is responsible for the development of allergic diseases. In response to different types 
of microbes, naive CD4+ T cells differentiate into distinct subsets of effector cells that 
produce different cytokines and therefore can perform diverse effector functions. 
Currently, T helper 1 (Th1) and T helper 2 (Th2) cells are the best defined subsets of 
effector T cells of the CD4+ helper lineage. The present understanding is that 
interleukin-4 (IL-4), which activates the transcription factors GATA3 and STAT6, 
induces the differentiation of naive T cells activated by antigen-presenting cells 
(APCs) into Th2 cells (12-14). These effector Th2 cells produce various cytokines 
like IL-4, IL-5 and IL-13, which are responsible for several effector functions: 
production of allergen-specific IgE by B cells, development and recruitment of 
eosinophils, production of mucus and contraction of smooth muscles as well as 
tissue homing of Th2 cells (12,13,15,16). Furthermore, IgE-mediated cross-linking of 
receptors and subsequent degranulation of basophils and mast cells is the main 
event in type I hypersensitivity, which may lead to allergic inflammation.  
Many intracellular bacteria, viruses and some parasites elicit innate immune 
reactions. DCs are induced to produce IL-12. IL-12 binds to receptors on antigen-
stimulated CD4+ T cells and activates the transcription factor STAT4 and T-bet, 
which promote the differentiation of T cells into Th1 cells. The Th1 subset is 
characterized by the secretion of interferon-γ (IFN-γ), the principal macrophage-
activating cytokine, and has important functions in innate and adaptive cell-mediated 
immunity. Importantly, Th1 cells may contribute to chronicity and effector phase in 
allergic diseases, although Th2 cells are responsible for the development of allergic 
diseases (17-22). For instance, IFN-γ up-regulates Fas on keratinocytes and makes 
them susceptible to apoptosis, which is an essential pathogenetic event in 
eczematous dermatitis (18,23). In asthma, tumour necrosis factor-α (TNF-α) and 
IFN-γ cause epithelial shedding because they induce bronchial epithelial apoptosis 
(18).  
Introduction
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Not only the effector functions, but also development and expansion of the 
Th1 or Th2 subsets are dependent on their produced cytokines. IFN-γ secreted by 
Th1 cells enhances further Th1 differentiation and prevents the proliferation of Th2 
cells. IL-4 produced by Th2 cells promotes Th2 differentiation and inhibits activation 
of Th1 cells. Therefore, each subset amplifies itself and simultaneously, counter-
regulates the other subset (24).  
 
5.2.2 B cells 
B cells are antibody-producing cells, which play an important role in the humoral 
immunity. They mature within the bone marrow and when they leave, each B cell 
expresses a unique antigen-binding antibody molecule on the cell surface, which is 
also called B-cell receptor (BCR). An immature B cell, which has never been 
exposed to an antigen is known as naive B cell, and expresses only cell surface 
bound IgM. When reaching maturity, these cells start to express both IgM and IgD 
with identical antigen binding regions, and are ready to respond to antigen (25). 
When such a B cell first encounters an antigen that matches its membrane-bound 
receptor, the B cell starts to proliferate rapidly; its progeny differentiate into memory 
B cells and effector B cells termed plasma cells. Approximately 60% of naive B 
lymphocytes and 40% of memory B lymphocytes are found in human peripheral 
blood (26). Memory B cells have a longer lifespan than naive cells and survive for 
several years. This allows the immune system to remember an antigen and respond 
faster upon future exposures (27). In contrast, naive B cells live only for about 6 
weeks in humans or 1-3 months in mice. Furthermore, memory B cells express the 
same BCR as their parent B cell. Plasma cells are specialized to secrete huge 
amounts of the antibodies produced and they express little or no membrane-bound 
antibody. It is believed that a single plasma cell can secrete more than 2000 
molecules per second (28). 
Membrane IgD expression has been used in several studies to distinguish 
between naive and memory B lymphocytes (29,30). Both subsets can be further 
separated according to the expression of IgA, IgD, IgG, and IgM. All naive B 
lymphocytes are IgD+IgM+CD27-. Memory B lymphocytes, however, can be 
IgD+IgM+CD27+, IgD-IgM+CD27+, or IgG+/IgA+CD27+, representing, respectively, 15, 
10, and 15% of circulating B lymphocytes (26). 
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5.2.2.1 Antibodies  
Antibodies are found in blood or other body fluids of vertebrates. They are Y-shaped 
glycoproteins and their main function comprises identifying and neutralizing foreign 
objects, such as bacteria and viruses. Each molecule consists of two large heavy 
chains and two small light chains. Two identical heavy chains and two identical light 
chains, which are arranged into two Fab regions and an Fc region and are separated 
by a flexible hinge region, compose the monomeric structural and basic functional 
unit of an immunoglobulin (Fig. 1). An antigen is recognized by the paired variable 
regions at the tips of the Fab arms, while the Fc region interacts with various 
receptors and effector molecules. Antibodies are also called immunoglobulins, 
because the heavy and light chains have a characteristic tertiary structure of 
antiparallel β sheets, which are termed globular domains. Based on differences in the 
heavy chain C regions, five distinct antibody isotypes have been identified in 
mammals, known as IgA, IgD, IgE, IgG and IgM, which perform different roles, and 
help to elicit the appropriate immune response against different types of foreign 
objects they encounter (31). Secreted antibodies can also be dimeric with two Ig 
units like IgA or pentameric with five Ig units, like mammalian IgM (32). Random 
combinations of gene segments that encode different antigen binding sites (or 
paratopes), followed by random mutations in this area of the antibody gene create a 
huge and diverse population of antibodies (33). Furthermore, antibody genes also 
reorganize in a process, which is called class switching. During this process, a 
variable region from one type of heavy chain is relocated to another, therefore 
creating another isotype of the antibody. By this means can a unique antigen-specific 
antibody be used by several different parts of the immune system. Therefore, 
antibodies are an essential component of the adaptive immune system that adapts 
and remembers responses to invading pathogens. Antibody production is the main 
function of the humoral immune system (34). 
 
 
 
 
 
 
 
Introduction
 
 18 
 
Figure 1. Schematic diagram of an antibody molecule. VL: variable light chain; VH: 
variable heavy chain; CL: light chain constant region; CH: heavy chain constant 
region. 
 
5.2.2.2 Class switching 
Class switching proceeds in the heavy chain gene locus by a mechanism called 
class switch recombination (CSR), which allows different daughter cells from the 
same activated B cell to produce different antibody isotypes. Initiation of this process 
requires two signals. The first one is delivered by cytokines, which target specific CH 
genes for transcription, the second one is delivered in the case of T-dependent 
antigens by interaction of CD40 on B cells with its ligand CD40L on activated T cells 
(35). Triggering of CD40 on B cells by CD40L activates NF-κB-Rel (36), which binds 
to cis-acting κB elements within intronic IH promoters 5’ of switch (S) regions and 
leads to germline IH-S-CH transcription (37). S regions are conserved nucleotide 
motifs, which are found in DNA upstream of each constant region gene (except in the 
δ-chain). Germline transcription induces chromatin opening and facilitates the 
recruitment of activation-induced cytidine deaminase (AID). Deamination of cytosine 
residues in single-stranded DNA in the S regions by the AID leads to S region 
double-stranded breaks (38-40). Recombination of the two S regions and deletion of 
Introduction
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the DNA-loop juxtaposes the somatically recombined VHDJH exon to another CH 
gene (41,42). Cells producing one Ig isotype have deleted all rearranged CH genes 5’ 
of this isotype. During class switching, only the constant region of the antibody heavy 
chain changes. The variable regions, however, and therefore antigen specificity, 
remain the same. Thus the progeny of a single B cell can produce antibodies, which 
are all specific for the same antigen, but these antibodies have the ability to change 
the effector function towards an appropriate antigenic challenge. The isotype 
generated depends on which cytokines are present in the B cell environment (43). 
 
5.2.2.3 Antibody isotypes 
5.2.2.3.1 Immunoglobulin G (IgG) 
The most abundant isotype in serum is IgG, which constitutes about 80% of the total 
serum immunoglobulin. Four human IgG subclasses exist, and they are numbered 
according to their decreasing average serum concentrations: IgG1, IgG2, IgG3, and 
IgG4. A different size of the hinge region and the number and position of the 
interchain disulfide bonds between the heavy chains make these four molecules 
distinguishable between each other and affect the biological activity of the molecule. 
IgG1 is able to cross the placenta and to protect the developing fetus. It has a high 
affinity to Fc receptors on phagocytic cells and therefore is very efficient in 
opsonizing foreign molecules. It has an intermediate capacity to activate 
complement. 
IgG2 does not cross the placenta and because of the very low affinity to Fc 
receptors, it is weak in activating complement and opsonizing molecules. 
IgG3 has the same features as IgG1, but it is the most efficient activator of 
the complement (28). 
IgG4 has an intermediate affinity for Fc receptors. It is a monovalent, non-
inflammatory antibody isotype because the half-molecules (one H plus one L-chain) 
can separate and pair again. Hence, bispecific antibodies are formed, which are 
unable to form large immune complexes and have a low potential to induce 
inflammation (44). Furthermore, IgG4 does not fix complement and as a blocking 
antibody, it competes with IgE antibodies for allergen and thus dampens IgE-
mediated immune reactivity. Only when two antigens are present at the same time in 
the body and high levels of IgG4 antibodies are induced, significant amounts of 
bispecific antibody will be generated. The breaking of inter-heavy chain disulfide 
bonds, which are located in the hinge region, requires a reducing environment and is 
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believed to occur in the extracellular milieu, in blood or at cell surfaces. Furthermore, 
another important antibody heavy chain interface, which needs to be broken for the 
half-molecule exchange, is located between the CH3 domains (45). 
There are 5 different types of Fcγ receptors (FcγR) existing, which have 
different affinities for heavy chains of different IgG subclasses. So far, two general 
classes of FcγR have been identified: the activation receptors, FcγRI (CD64; Kd ~ 10-
9M), FcγRIIA (CD32; Kd ~ 10-7M), FcγRIIIA (CD16; Kd ~ 10-6M), FcγRIIIB (CD16; Kd ~ 
10-6M), characterized by the presence of a cytoplasmic ITAM sequence either 
intrinsic to the receptor or as part of an associated subunit, the γ or ζ chain, and the 
inhibitory receptor, FcγRIIB (CD32; Kd ~ 10-6M) characterized by the presence of an 
ITIM sequence. Most effector cells of the immune system express activation FcγRs, 
notably monocytes, macrophages, NK cells, mast cells, eosinophils, neutrophils, and 
platelets, while they are not found on lymphoid cells. With the exception of T cells 
and NK cells, FcγRIIB is expressed on all cells of the immune system, and it is the 
only Fc receptor on B cells where it inhibits BCR-generated calcium mobilization and 
cellular proliferation (46,47). The activation receptors trigger different effector 
responses such as degranulation, phagocytosis, antibody-dependent cell-mediated 
cytotoxicity (ADCC), transcription of cytokine genes and release of inflammatory 
mediators (48-50). Normally, activation and inhibitory receptors are coexpressed on 
the cell surface and function in concert. Therefore, the outcome of the physiological 
response is the interplay of the contrary activation and inhibitory signaling pathways, 
and is determined by the level of expression of each receptor and the selective 
avidity of the IgG ligand. The expression and thus also the ratio of activating to 
inhibitory Fc receptors is regulated by exogenous factors. Cytokines like IL-4, IL-10, 
or TGF-β upregulate FcγRIIB, thereby, thresholds for cell activation are high, 
whereas inflammatory cytokines downregulate the inhibitory and upregulate the 
activating FcRs. However, that cytokine-mediated regulation of FcR expression is 
cell type-specific. Moreover, FcγRIIB has been suggested to play an important role in 
maintaining periperal tolerance. Homo-aggregation of FcγRIIB leads to B cell 
apoptosis via another signaling pathway and is responsible for deletion of low-affinity 
or self-reactive B cells that have undergone somatic hypermutation (SHM) (51). 
 
5.2.2.3.2 Immunoglobulin A (IgA) 
Although IgA constitutes only 10%-15% of the total immunoglobulin in serum, it is the 
predominant immunoglobulin class in external secretions such as breast milk, saliva, 
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tears, and mucus of the bronchial, genitourinary, and digestive tracts. These mucous 
membrane surfaces are the main entry sites for most pathogenic organisms. 
Secretory IgA, which is found in external secretions, consists of a dimer or tetramer, 
a J-chain polypeptide, and a polypeptide chain called secretory component. The 
secretory component comprises five immunoglobulin-like domains that bind to the Fc 
region domains of the IgA dimer. It is a fragment of the poly-Ig receptor, which 
transports polymeric IgA across cell membranes, and is expressed on the basolateral 
surface of most mucosal epithelia as well as on glandular epithelia in the mammary, 
salivary, and lacrimal glands. The secretory component masks sites susceptible to 
protease cleavage in the hinge region, allowing the IgA molecule to exist longer in 
the protease-rich mucosal environment. Pentameric IgM is also transported into 
mucous secretions by this mechanism. IgA-secreting plasma cells reside along 
mucous membrane surfaces. Every day, a human secretes from 5 g to 15 g of 
secretory IgA onto mucous secretions, where it can cross-link large antigens with 
multiple epitopes. The most important function of secretory IgA is binding to bacterial 
and viral surface antigens, so that the pathogens are not able to attach to the 
mucosal cells, thus avoiding viral infection and bacterial colonization. Complexes of 
secretory IgA and antigen are finally eliminated by the ciliated epithelial cells of the 
respiratory tract or by peristalsis of the gut (28). 
In humans, two subclasses of IgA, IgA1 and IgA2, exist, which are encoded 
by separate genes. Several sequence differences are found in their heavy chain 
constant regions. A major difference between the subclasses has been discovered in 
the hinge region, which is very extended in IgA1. Serum IgA exists mainly as a 
monomer, predominantly (∼90%) of the IgA1 subclass and is produced in the bone 
marrow, while polymeric secretory IgA consists mainly of the IgA2 subclass.  
Human FcαRI (CD89) is constitutively expressed on neutrophils, monocytes, 
eosinophils, some macrophages, interstitial DCs, and Kupffer cells. In blood and 
tissues, neutrophils make up the majority of FcαRI-positive cells (52). Peritoneal fluid 
and bronchoalveolar lavage fluid were found to contain newly emigrated CD89+ 
macrophages (52). Binding of antigen-complexed IgA to FcαRI elicits distinct 
biological responses depending on the cell type involved. These responses include 
antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, release of 
cytokines, superoxide generation, calcium mobilization, degranulation, and antigen 
presentation (53). In a recent study, it has been shown that crosslinking of FcαRI 
triggers NADPH oxidase activation, which produces activated oxygen species, and 
degranulation in blood-derived eosinophils (54). 
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5.2.2.3.3 Immunoglobulin E (IgE) 
In healthy individuals, IgE is found at an extremely low serum concentration (~0.3 
µg/ml), but its biological activity is extremely potent.  There are two IgE Fc receptors 
existing. The low-affinity IgE receptor (CD23, FcεRII), expressed on B cells and 
macrophages (55,56), and the high-affinity IgE receptor (FcεRI), present on 
monocytes, DCs and Langerhans cells of allergic patients (57-59). CD23 can be 
internalized and transports IgE into the antigen-processing pathway, followed by 
presentation of antigen peptides on the MHC class II molecules, thereby facilitating 
the presentation of allergens to T cells and resulting in extremely efficient T cell 
activation. But FcεRI is also able to directly present IgE-bound allergen to specific T 
cells. It has been shown that in the presence of IgE, antigen uptake and subsequent 
presentation was increased 100- to 1,000-fold (60). This means, an allergen present 
at extremely low doses can activate allergen-specific T cells very efficiently via IgE-
mediated allergen-presentation, whereas ordinary antigen uptake by APCs via 
endocytosis or micropinocytosis needs a high antigen concentration. Several 
publications have shown that strong expression of FcεRI on basophils and mast cells 
critically depends on the presence of IgE molecules (61-63). Treatment with anti-IgE 
mAb leads to an enormous decrease of both serum IgE levels, and the levels of 
FcεRI expressed on peripheral blood basophils and DCs (64-66). 
Atopic individuals have a hereditary predisposition to produce IgE antibodies 
against common environmental antigens and are therefore more susceptible to 
allergic diseases (67,68). Allergic patients show a strong immune response to 
innocuous proteins, which should be ignored, because they do not endanger the 
organism. The cytokines of allergen-specific Th2 cells play a crucial role in the 
induction of IgE and eosinophilia, factors, which are involved in the immediate 
hypersensitivity reaction and late-phase responses, respectively. The classical type I 
IgE-mediated allergic response can be divided into an immediate- and a late-phase 
response. Allergen-specific crosslinking of IgE bound to the high-affinity IgE receptor 
on mast cells and basophils leads to the release of inflammatory mediators such as 
histamine, leukotrienes, and prostaglandins. This results in an immediate 
hypersensitivity reaction within 5–30 min that lasts for ~1 h. Subsequently, most 
patients develop a late-phase reaction, which is characterized by the recruitment and 
persistence of eosinophils, basophils and activated CD4+ T cells at the sites of 
allergen exposure, and can manifest as nasal or airway obstruction. Generally, late-
phase responses last maximal 6–12 h following the immediate reaction and 
disappear within 24 h (67).  
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Helminth infections, which are chronic and longlasting, are known to be 
associated with eosinophil and IgE production and also induce a Th2 immune 
response. Paradoxically, there is a general observation that the >1 billion people 
currently infected with helminth parasites, have a lower prevalence of atopy and 
allergic disorders. Infected individuals usually develop anti-inflammatory networks 
(IL-10, TGF-β and Tregs) to control the tissue damage that would otherwise result 
from the continuous challenge of the immune system by foreign antigens, which are 
permanently released by metybolically active worms (69). 
 
5.2.2.3.4 Immunoglobulin D (IgD) 
IgD accounts for about 0.2% of the total serum immunoglobulin and the average 
serum concentration is 30 µg/ml. IgD, together with IgM, constitutes the BCR of 
mature B cells. But no biological effector function has been identified for this 
immunoglobulin isotype (28). 
 
5.2.2.3.5 Immunoglobulin M (IgM) 
Plasma cells secrete IgM as a pentamer. In a primary response to an antigen, IgM is 
the first immunoglobulin class produced, and it is also the first immunoglobulin 
synthesized by neonates. IgM has a serum concentration of 1.5 mg/ml and 
constitutes 5%-10% of the total immunoglobulin in serum. In the intercellular tissue 
fluids, only very low amouts of IgM are found due to its large size. As the pentameric 
molecule also contains the J chain, IgM can bind to the poly-Ig receptors on 
secretory cells, which transport it across epithelial linings to mucosal surfaces. IgM 
activates complement very efficiently, even more than IgG does, because due to the 
pentameric form more than two Fc regions are brought in close proximity, which is 
required for complement activation (28). 
 
5.2.2.4 Biological activities of antibodies 
5.2.2.4.1 Neutralization 
To replicate and proliferate, viruses and intracellular bacteria must enter a cell, and 
they usually bind to specific molecules on the cell surface for invading. This event 
can be avoided by pathogen-specific antibodies that constrain the pathogen to dock 
to its preferred receptor (34). Some antibodies, like IgA, directly bind to microbes in 
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mucus to prevent colonization of mucosal tissues, and those found in anti-venoms 
neutralize toxins by binding to them (70). 
 
5.2.2.4.2 Activation of complement 
Antibodies that bind to antigens on the surface of microbes attract the first 
component of the complement cascade (complement protein C1) with their Fc region 
and activate the "classical" complement system (71). Subsequently, the bacteria can 
be killed in two ways (34). First, the binding of the antibody and complement 
fragments on the surface marks the microbe and targets it for phagocytosis. Second, 
the terminal components of complement cascade form a membrane attack complex 
to kill the bacterium directly (72). 
 
5.2.2.4.3 Activation of effector cells 
Effector cells, which express Fc receptors interact with the bound IgA, IgG, or IgE 
antibodies (34). This interaction of a particular antibody isotype with the Fc receptor 
on a particular cell triggers a specific effector function of that cell; for example 
phagocytes phagocytose, mast cells and neutrophils degranulate, natural killer cells 
release cytokines such as IFN-γ and cytotoxic molecules. Eosinophils are activated 
by FcεRI-induced signals and release their granule contents, which finally results in 
deletion of the pathogen (73). 
 
5.2.2.5 Immunoglobulin diversity 
Diversity is a fundamental feature of the adaptive immune system. For a successful 
recognition and eradication of many different types of microbes, a huge diversity 
among antibodies is required. This is achieved by variability in the amino acid 
composition of the antigen-binding sites of an antibody molecule. Consequently, 
antibodies are able to interact with many different antigens (74). It has been 
estimated that humans produce about 10 billion different antibodies, each capable of 
binding a different epitope (75). Although an enormous repertoire of different 
antibodies can be generated in a single individual, the number of genes available for 
these proteins is limited. There are several genetic mechanisms existing, like 
combinatorial and junctional diversity, that enable B cells to generate a diverse pool 
of antibodies from a relatively small number of antibody genes (76). 
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Table 2. Immunoglobulin isotypes 
Features 
 
IgG1 IgG2 IgG3 IgG4 IgA1 IgA2 IgE IgM IgD 
Molecular 
weight  150’000 150’000 150’000 150’000 
150’000-
600’000 
150’000-
600’000 190’000 900’000 150’000 
% of the total 
serum 
immunoglobulin 
         
       
      
5-10% 
 
0.2% 
Normal serum 
levels (mg/ml) 9 3 1 0.5 3 0.5 0.0003 1.5 0.03 
In vivo serum 
half life (days) 23 
 
23 8 23 6 6 
 
2.5 5 3 
Activation of 
classical 
complement 
pathway 
+ +/- ++ - - - - +++ - 
Crossing of 
placenta + +/- + + - - - - - 
Present on 
membrane of 
mature B cells - - - - - - - + + 
Mucosal 
transport - - - - ++ ++ - + - 
Induces mast 
cell 
degranulation 
- - - - - - + - - 
Activity levels indicated as follows: ++ = high; + = moderate; +/- = minimal; - = none 
IgG, IgE and IgD always exist as monomers; IgA can exist as monomer, dimer, trimer, or 
tetramer. Membrane-bound IgM is a monomer, secreted IgM is a pentamer. Adapted from 
Goldsby et al., Immunology. Fifth ed. New York: Freeman 2003. 
 
 
5.3  Peripheral tolerance 
Mechanisms like activation-induced cell death, anergy and/or immune response 
modulation by T regulatory cells (Treg) are essential for the maintenance of 
peripheral T cell tolerance. The reason why some individuals develop atopic 
disorders upon exposure to allergens, and simultaneously, others are unaffected, is 
still not understood. However, it is obvious that a strong interaction of environmental 
and genetic factors have an influence. An allergic inflammation can be divided into 
four main processes (Fig. 2): (I) activation of memory/effector T cells and mast cells, 
eosinophils and basophils, (II) organ-selective homing of those cells, (III) prolonged 
survival and (IV) reactivation in the allergic organs and initiation of effector functions 
(77). In an allergic inflammation, T cells are activated by aeroallergens, food 
antigens, autoantigens or bacterial superantigens (78,79). Simultaneously, the skin, 
lung- or nose-related chemokine network affects the T cells and they show organ-
selective homing (80-82). In the subepithelial tissues, the inflammatory cells show a 
prolonged survival, interact with resident cells of the organ and are reactivated 
80% 10-15% 
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(83,84). In atopic dermatitis and asthma, T cells induce IgE production, eosinophil 
survival and mucus hyperproduction as effector functions (84-86). Furthermore, 
activated T cells cause bronchial epithelial cell and keratinocyte apoptosis (17-20). 
Since all those pathological events are dependent on T-cell activation, peripheral T-
cell tolerance to allergens can avoid an allergic inflammation. 
A critical event in a healthy immune response to allergens as well as in a 
successful allergen-specific immunotherapy is the development of an allergen-
specific effector T cell response towards a Treg cell response (87). Treg cells prevent 
allergen-specific T cell proliferation and suppress secretion of Th1- and Th2-type 
cytokines. Effector cells of an allergic inflammation, like mast cells, basophils and 
eosinophils, can also be suppressed by Treg cells, either directly or indirectly (88). 
During SIT, histamine, released in high amounts by mast cells and basophils, 
contributes to the peripheral tolerance in different ways. It induces production of IL-
10 by DCs (89) and Th2 cells (90). In addition, it increases the suppressive activity of 
TGF-β on T cells (91). All these effects are mediated via HR2, a cAMP-associated G-
protein coupled receptor, which is highly expressed on Th2 cells and suppresses IL-4 
and IL-13 production and T-cell proliferation (92). Therefore, HR2 probably plays an 
important role in induction of peripheral tolerance or in active suppression of 
inflammatory/immune responses. 
 
 
 
 
Figure 2. Allergic inflammation is characterized by four sequential processes. 
Several antigens or yet undiscovered factors activate T cells, which subsequently 
undergo organ-selective homing controlled by organ-related chemokine networks. In 
Introduction
 
 27 
subepithelial tissues, T cells show increased survival due to contacting the 
extracellular matrix and the cytokines produced in the surroundings, and are 
continuously stimulated by antigens and superantigens. These activated T cells 
produce and secrete cytokines, which elicit different effector functions, including 
apoptosis of the organ cells, hyper-IgE and eosinophilia. Adapted from Taylor et al., 
2004, Int Arch Allergy Immunol, 135, 73-82. 
 
5.3.1 T regulatory cells and their cytokines 
Immunological tolerance is mediated by central and peripheral mechanisms. Those 
mechanisms include clonal deletion as well as induction of unresponsiveness in 
antigen-specific effector T cells. The latter is performed via active suppression by T 
regulatory cells and is essential for induction of peripheral tolerance to both self and 
foreign antigens in vivo. T cells with suppressive capacity were first described in the 
early 1970s by Gershon (93,94). Up to now, many distinct types of T regulatory cells 
have been described (Table 3), which can roughly be divided into natural or inducible 
Tregs. The three most common subtypes are discussed below. 
 
Table 3. Types of regulatory T cells 
Treg cell type Suppressor mechanism 
Tr1 IL-10, TGF-β, CTLA-4, PD-1 
CD4+CD25+ IL-10, TGF-β, CTLA-4, PD-1, GITR 
Th3 TGF-β 
CD8+CD25+CD28- Same as CD4+CD25+ 
Qa-1-dependent CD8+ Qa-1-specific TCR 
CD4-CD8- Induction of apoptosis 
TCR γδ IL-10, TGF-β 
Adapted from Taylor A. et al., Microbes Infect. 2005; 7: 1049-55. 
 
 
5.3.1.1 Type 1 T regulatory cells (Tr1) 
Tr1 cells, also known as adaptive or inducible Tregs, suppress effector T cells in a 
contact-independent manner by secretion of IL-10 (95) and TGF-β (96,97). Whether 
an immune respone against common environmental proteins leads to tolerance or 
allergy depends on a fine balance between allergen-specific Tr1 cells and allergen-
Introduction
 
 28 
specific Th2 cells (87). It has been observed that in beekeepers, who have a natural 
tolerance to phospholipase A2 (PLA2), the major allergen of bee venom, or in 
patients who underwent SIT, induction of anergy correlates with a considerable 
increase of IL-10-producing T cells. Neutralisation of endogenous IL-10 fully 
reconstitutes T-cell proliferation to PLA2 in vitro (98). By using IFN-γ-, IL-4- and IL-10-
secreting allergen-specific CD4+ T cells that represent Th1-, Th2- and Tr1-like cells, 
respectively, it has been found that both healthy and allergic individuals have all 
three subsets, however, in different proportions. In healthy individuals, the dominant 
subset specific for common environmental allergens are Tr1 cells, whereas in allergic 
individuals, allergen-specific IL-4-secreting T cells are the most frequent subset. 
Therefore, the development of either allergy or a healthy immune response is 
dependent on the frequency of allergen-specific effector Th2 cells or T regulatory 
cells (87). Human and mouse naive CD4+ T cells cultured in vitro together with 
vitamin D3 and dexamethasone differentiate into Tr1 cells, which produce only IL-10 
(99). Additionally, IL-10, IFN-α or a combination of IL-4 and IL-10 can also lead naive 
CD4+ T cells to differentiate into Tr1 cells in vitro, however, these generated cells 
produce also moderate amounts of IFN-γ and IL-5 (100-102). Tr1 cells are not 
anergic and can efficiently proliferate in vivo (103). For proliferation in vitro, they 
need IL-2, IL-4, IL-7 and IL-15 (87). 
Tr1 cells, and also CD4+CD25+ Treg cells, constitutively express cytotoxic T 
lymphocyte antigen-4 (CTLA-4), whereas naive T cells express this molecule only 
after they have been activated. CTLA-4 is a co-stimulatory receptor of the CD28 
family and transduces negative signalling in activated effector T cells, but also 
contributes to Treg cell-mediated suppression. In vitro, blocking of CTLA-4 abrogates 
the suppressive effect of Treg cells in humans (104). Treatment of young naive mice 
with monoclonal antibody to CTLA-4 elicits autoimmune disease without reducing the 
Treg cell number (105). It is suggested that signals via CTLA-4 and TCR together 
induce the suppressive activity of Treg cells. 
A subset of human Tr1 cells expresses programmed death-1 (PD-1), which 
also belongs to the CD28 family. PD-1 is an immunoreceptor tyrosine-based 
inhibitory motif–containing receptor expressed upon T cell activation and probably 
has an inhibitory effect in immune responses, as PD-1–deleted mice develop 
autoimmune diseases (106). Ligands for PD-1 are PD-ligand (L)1 and PD-L2, 
members of the B7 family. Binding of PD-L to PD-1 on murine CD4 and CD8 T cells 
leads to inhibition of proliferation and cytokine production. T cells stimulated with 
anti-CD3/PD-L1Fc-coated beads show dramatically decreased proliferation and IL-2 
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production (107).  
Tr1 cells which are specific for different antigens arise in vivo (108). One 
allergen-specific Tr1 cell can be found in 1'000 to 20'000 of the total CD4+ T cell 
population and the antigen-specific suppressive activity of Tr1 cells can be observed 
already at very low numbers. If the number of cells is very high and sufficient 
quantities of suppressor signals are around, Tr1 cells also show nonspecific 
suppression. If the outcome of an immune response is more stimulating or more 
suppressive might be depending on the T cell which first contacts an APC. In case 
the first T cell is a Tr1 cell, it may inhibit the maturation of APC, since IL-10 down-
regulates the antigen-presenting capacity, such as HLA-DR expression, 
costimulatory molecules, and several cytokines in DCs and monocytes or 
macrophages (109). IL-10-secreting T cells seem to be able to regulate the functional 
state of APCs in a way that these APCs can then promote the generation of more 
Tr1 cells. 
 
5.3.1.2 CD4+CD25+ T regulatory cells 
The natural Treg cells or CD4+CD25+ T cells characterized by high levels of CD25 
(IL-2Rα-chain) and FoxP3 expression originate in the thymus, but they can also be 
generated in the periphery (110). FoxP3 belongs to the forkhead/winged-helix family 
of transcription factors and is belived to be the main regulator in the development 
and function of CD4+CD25+ Treg cells (110). On average, the frequency of 
CD4+CD25+ T cells is approximately 3% in total PBMCs and 5-10% in peripheral 
CD4+ T cells. They strongly suppress the proliferation of both naive and memory 
CD4+CD25- T cells to alloantigens (111). Their profile of cytokine production is very 
similar to that of Tr1 cells. But for their suppressive effects, neither IL-10 nor TGF-β 
seems to be directly required (111). However, suppression requires activation of 
suppressor T cells by TCR ligands or anti-CD3 antibodies (112), but interestingly, 
suppression occurs in an antigen-non-specific manner (113). In addition, they 
express the surface markers CTLA-4 (114) and PD-1, which are important for their 
suppressive activity, but also glucocorticoid-induced tumour necrosis factor receptor 
(GITR) (115). GITR negatively regulates CD4+CD25+ Treg cell suppression, because 
binding of the soluble GITR ligand to GITR leads to loss of the anergic state of the 
cell (116). In the presence of IL-2, human CD4+CD25+ T cells can be expanded in 
vitro and cultured cells retain their suppressive capacities. If CD4+CD25+ T cells are 
eliminated, various diseases in genetically susceptible hosts develop spontaneously. 
The X-linked immune dysregulation, polyendocrinopathy and enteropathy syndrome 
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(IPEX), in which the FOXP3 gene is mutated and CD4+CD25+ Treg cells are 
nonfunctional, is characterized by an allergic phenotype with dermatitis and hyper 
IgE and an autoimmune phenotype with enteropathy, type I diabetes, thyroiditis, 
hemolytic anemia and thrombocytopenia (117,118). The role of CD4+CD25+FOXP3+ 
Treg cells in human allergies has been studied in acute atopic dermatitis lesions, 
where an impaired skin infiltration of CD4+CD25+FOXP3+ T cells could be observed 
(119). In asthmatic patients under glucocorticoid treatment, FOXP3mRNA expression 
was significantly increased (120). 
 
5.3.1.3 Th3 
Th3 cells produce high levels of TGF-β and like Tr1 cells, they are also inducible 
upon activation with an antigen or anti-CD3 antibody (96,121). Neutralizing 
antibodies against TGF-β and IL-10 revealed these cytokines to play a crucial role 
because the disease-protective effects of Th3 cells were abrogated. Furthermore, it 
has been shown that Th3 cells exert bystander immune suppression in vitro (96). 
 
5.3.1.4 Interleukin 10 
IL-10, the main cytokine produced by regulatory T cells, has anti-inflammatory 
features and it significantly inhibits the anti-CD28-induced proliferation. The tyrosine 
kinase Tyk-2, which is associated to the IL-10 receptor tyrosine phosphorylates SHP-
1 upon IL-10 binding. Within minutes, SHP-1 binds to CD28 and ICOS costimulatory 
receptors and dephosphorylates them. Thereafter, the binding of phosphatidylinositol 
3-kinase to CD28 and ICOS no longer occurs, and the downstream signaling is 
inhibited. Increased proliferation of spleen cells from SHP-1-deficient mice stimulated 
with CD28 and ICOS could be observed compared to spleen cells of wild-type mice 
(122). Only T cells stimulated by low numbers of triggered TCRs, which depend on 
CD28 stimulation, can be inhibited by IL-10 (123). In PBMCs, the proliferative T-cell 
response to various allergens was inhibited by IL-10, however, the proliferative 
responses of T cells, stimulated by anti-CD3, was not suppressed (123). IL-10 also 
indirectly suppresses T-cell responses by inhibiting the antigen-presenting capacity 
of APCs, like dendritic cells (DCs), Langerhans cells and macrophages. Expression 
of MHC class II and co-stimulatory molecules such as ICAM-1, CD80 and CD86 is 
downregulated and the secretion of cytokines and chemokines, which influence T-
cell differentiation, proliferation and migration is decreased (109). IL-10 does not only 
inhibit T cells but also activated monocytes and macrophages (124), however 
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through different mechanisms since monocytes and macrophages do not express 
CD28. In monocytes, the suppressor of the cytokine-signalling-3 (SOCS3) gene, 
which probably inhibits the Stat1-tyrosine phosphorylation induced by IFN, is induced 
by IL-10 (125). 
In mice, administration of IL-10 before allergen treatment leads to 
unresponsiveness of antigen-specific T-cells, which demonstrates the crucial role of 
IL-10 in induction/maintenance of peripheral T-cell tolerance (126). Moreover, 
prevention of graft-versus-host disease by IL-10 and allograft rejection in human 
leukocyte antigen-mismatched bone-marrow-transplanted severe combined 
immunodeficient patients provides additional evidence for the importance of this 
cytokine in the induction and maintenance of peripheral tolerance (127). Similarly, 
increased endogenous IL-10 production by tumor-reactive human T cells led to a 
reduced stimulation of these cells which also shows a role for IL-10 in tumor-specific 
tolerance (128). 
In B cells, IL-10 added during the first 3 days of in vitro culture has been 
shown to decrease ε transcript expression and IgE production induced by IL-4. But 
addition of IL-10 to B cells that already switched to IgE potentiated IgE production. 
IL-4-induced γ4 transcript expression and IgG4 production was upregulated by IL-10 
independent of the time of addition. IL-10 is not a switch factor for IgG4, but it seems 
to induce the growth and differentiation of cells that have already switched to IgG4 
and to synergize the IL-4-induced IgG4 production (129). 
 
5.3.1.5 TGF-β 
It has been demonstrated in several studies that CD4+CD25+ T cells produce high 
amounts of TGF-β in both mice and humans. Those cells express TGF-β in its active 
structure on the cell surface (130). Colitis in wild-type mice could be suppressed by 
CD4+CD25+ Treg cells from wild-type mice, but not by CD4+CD25+ cells from a 
transgenic mouse model with impaired TGF-β signalling specifically in T cells (131). 
TGF-β not only has suppressor activity, but it has also been shown to be important 
for the induction of CD4+CD25+ Treg cells in vitro and in vivo (132). In TCR-
stimulated T cells, TGF-β induces FOXP3 expression, surface expression of CD25, 
HLA-DR, GITR, CD103 and intracellular CTLA-4 (133). The generated cells do not 
respond to TCR stimulation, and do also produce TGF-β and IL-10, but they do not 
synthesize Th1 nor Th2 cytokines. In TGF-β1-/- mice a significantly reduced number 
of Tregs occurs in the periphery, although the Tregs develop normally in the thymus. 
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However, the Foxp3 expression is lower and cells are less suppressive, suggesting 
that TGF-β signaling is essential in maintaining Tregs in vivo. Not surprisingly, these 
mice develop severe autoimmunity (134). In mice, TGF-β toghether with IL-6 induces 
the differentiation of Th17 cells (135), which have been associated with many 
inflammatory diseases such as asthma, rheumatoid arthritis, lupus and allograft 
rejection (136,137). IL-17, the main cytokine produced by Th17 cells, has a 
proinflammatory function because it recruits neutrophils to inflammatory sites through 
the induction of granulocyte colony-stimulating factor and IL-8 (138). 
 
 
 
 
Figure 3. Treg cells control the immune responses elicited by Th1 or Th2 cells. 
IFN-γ released by Th1 cells activates B cells to produce IgG1 antibodies, whereas IL-
4 and IL-13 secreted by Th2 cells induces class switch to and production of IgE 
antibodies. Treg cells however, stimulate B cells to produce/secrete IgG4 and little 
amounts of IgA. Thus, Treg cells regulate antibody isotypes, which may contribute to 
the suppression of inflammatory dieseases by inducing IgG4 and by suppressing 
IgE. 
 
5.3.2 Tregs and the hygiene hypothesis 
Atopic disorders have been arising constantly during the past three decades and not 
only the frequency but also the severity of those disorders has been increasing, 
particularly in developing countries. Currently, 10-20% of children and 1-3% of adults 
in industrialized countries have atopic dermatitis (139). The hygiene hypothesis tries 
to explain the reason for this increase in Th2-associated allergic diseases (140). 
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Improved public health, the use of antibiotics and vaccines, which leads to a 
reduction in childhood infections, a decreased exposure to endotoxins, domestic 
animals or farms and changes in gut flora are all factors which seem to be 
associated to the enormous increase in allergies (141-144). It is thought that early 
childhood infections direct the immune response from a Th2 response to an anti-
allergic Th1 response (145). However, at the same time as Th2-mediated allergies 
increased in developed countries, the frequency of Th1-mediated autoimmune 
diseases also rose. Therefore, the hygiene hypothesis has been adapted to reflect 
both a deviation in the Th1- and Th2-responses (141). The adaptation of the immune 
response, which can be observed during parasitic helminth infections, is an 
exception to this pathogen-induced Th2-Th1 cytokine-shift paradigm, because, 
individuals with parasitic worm infections have Th2-polarized responses, similar to 
atopic individuals, however, they normally have reduced allergic responses. Hence, it 
is possible that the rise in allergic diseases in the developed world is due to a 
reduction in infections with microbes or parasites. Such infections might induce 
regulatory cells and cytokines to suppress allergic Th2 or autoimmune Th1 
responses (141,146-148). Most parasitic helminths infect humans chronically, it 
means for years or decades. The parasite gets tolerized through induction of the 
immune suppression. This chronic downregulation of the immune system evokes a 
regulatory environment that might protect the individual from allergies (146,149). 
 
 
5.4   The innate immune system 
The first reactions against microbes invading the body are mediated by the innate 
immunity, which subsequently induce responses of the adaptive immunity. The 
defense mechanisms of the innate immunity are in place even before infection and 
responses to infections are very rapid. These mechanisms are specific for structures 
that are common to groups of related microbes and do not react to noninfectious 
substances, however, they cannot differentiate tiny distinctions between foreign 
substances. Furthermore, repeated infections evoke essentially the same responses. 
The main components of the innate immune system are (I) physical and chemical 
barriers, such as epithelia and antimicrobial substances produced at epithelial 
surfaces; (II) phagocytic cells (macrophages, neutrophils) and NK cells; (III) proteins 
of the complement system and other mediators of inflammation; (IV) cytokines that 
govern many activities of the cells of innate immunity. Receptors of the innate 
immune system bind conserved pathogenic particles called pathogen-associated 
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molecular patterns (PAMPs) that are only present on microbial pathogens and not on 
mammalian cells. 
 
5.4.1 Toll-like receptors 
Toll-like receptors (TLRs) are specific for microbial products including bacteria, 
viruses, fungal and protozoal components and can trigger innate immunity (150,151). 
They are type I integral membrane glycoproteins and consist of a leucine-rich repeat 
(LRR) domain flanked by characteristic cysteine-rich motifs in their extracellular 
regions and a toll/interleukin-1 receptor (TIR) domain in their cytoplasmic region, and 
these domains are highly conserved. So far, 13 distinct mammalian TLRs have been 
classified, 10 of which are found in humans. Some TLRs, such as TLR1, TLR2, 
TLR4, TLR5 and TLR6, are present on the plasma membrane, whereas others, such 
as TLR3, TLR7, TLR8 and TLR9, are present in the endosome. TLR2 binds zymosan 
(152), TLR3 oligomerizes in the presence of double-stranded RNA (153), the ligand 
for TLR4 is LPS, TLR5 binds flagellin (154), TLR7 interacts with single-stranded 
RNA, TLR8 recognizes single-stranded RNA and imidazoquinoline and TLR9 binds 
to CpG-containing DNA (155). After binding of the ligand, TLRs dimerize and 
subsequent conformational change results in recruitment of downstream signalling 
molecules. However, some TLRs are able to heterodimerize, which leads to an 
extension of the repertoire of specificities of the TLR system. TLR1/TLR2 bind triacyl 
lipopeptides, TLR2/TLR6 bind diacyl lipopeptides (156). 
With the exception of TLR3 are all TLRs linked to the adaptor molecule 
myeloid differentiation factor 88 (MyD88) and finally, the nuclear factor (NF)-κB gets 
activated (157). MyD88 has an N-terminal death domain (DD) and a C-terminal TIR 
domain. Currently, there are four more cytosolic TIR-containing adapter proteins 
known, Mal (MyD88-adapter like, also called TIRAP), TRIF (TIR domain-containing 
adapter-inducing interferon-β, also called TICAM-1), TRAM (TRIF-related adaptor 
molecule, also called TICAM-2) and SARM (sterile a- and armadillo-motif-containing 
protein). TLR3 and also TLR4 are coupled to TRIF that leads to the activation of NF-
κB and production of type I interferon (IFN). Activation of TLR2 and TLR5 does not 
induce type I IFN (158-160), however, triggering of TLR7, TLR8 and TLR9 also 
induces type I IFN production, but through different signalling pathways than via 
TLR3/4-activation (161,162).   
TLR stimulation on DCs, which are responsible for priming naive T cells 
(163), induces upregulation of MHC and costimulatory molecules, production of IFN-
α, and proinflammatory cytokines such as TNF-α, IL-1 and IL-6 as well as the 
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regulatory cytokines IL-12 and IL-18, which promote Th1 differentiation (164). In 
MyD88 deficient mice, an increase of Th2 responses with strong IgE production can 
be observed (165). In mammals, two different DC subsets exist, the myeloid and 
plasmacytoid DCs. The myeloid DCs (mDC) are similar to monocytes, secrete IL-12, 
and express TLR2 and TLR4. 8-16 hours after induction of DC maturation, IL-12 
production is exhaused and Th2 responses are induced (166). Plasmacytoid DCs 
(pDC) look like plasma cells, produce high amounts of IFN-α, express TLR7 and 
TLR9 and induce Th1 differentiation, but like mDCs, when their IFN-α-producing 
capacity is exhausted, they induce Th2 polarization (167). Moreover, Langenkamp et 
al. showed that high doses of antigen favor Th1, whereas low doses favor Th2 
responses (166).  
TGF-β and IL-10 have been shown to be involved in negative regulation of 
TLR-mediated signalling. TGF-β1 suppresses LPS-mediated responses and inhibits 
TLR4 expression (168). It also induces MyD88 degradation via ubiquitination (169). 
IL-10 inhibits pro-inflammatory cytokine production through LPS, and in human DCs, 
it downregulates IL-12 produced via TLR3- and TLR4-mediated signalling (170). 
Triggering of TLR7 and TLR9, which are expressed by B cells and pDCs, 
needs internalization of the ligand. Both cell subsets are poorly phagocytic, however, 
they can efficiently internalize BCR- or FcγRIIA-bound molecules. Therefore, B cells 
bearing a BCR, which recognizes RNA- or DNA-containing molecular complexes, 
can efficiently transport these complexes to TLR7 and TLR9 in the endosome. pDCs 
deliver RNA- and DNA-containing IgG immune complexes bound to FcγRIIA to 
endosomal TLR7 and TLR9. Leadbetter et al. showed that DNA-containing 
chromatin–IgG complexes could induce autoreactive B cells to produce antibodies 
against self-IgG (rheumatoid factors) by sequentially engaging BCR and TLR9 (171). 
In a similar study, RNA-associated autoantigens stimulated autoantibody production 
by engaging BCR and TLR7 in a sequential fashion and this response was strongly 
enhanced by IFN-α (172). In mouse models of systemic lupus erythematosus (lpr/lpr 
mice), it has been shown that defects in the TLR7 and/or TLR9 signaling pathways 
diminish the disease and that specific antibody production changed in a predictable 
way. Antibodies to both DNA and RNA were produced in lpr/lpr mice, whereas in 
MyD88-/- lpr/lpr mice, which are deficient in both TLR7 and TLR9 signaling, 
antibodies to nucleic acids were absent (172). TLR9-deficient lpr/lpr mice, however, 
are unable to produce anti-DNA antibodies but anti-RNA antibodies are still present 
(172,173). Moreover, RNA-specific antibodies are not found in mice that lack TLR7 
(174). 
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5.4.2 TLRs and other innate stimuli in thymus-independent B cell 
responses 
In the absence of T cell help, B cells can be activated by highly repetitive structures 
which are expressed on the surface of pathogens and which crosslink the BCRs. 
Splenic marginal zone B cells join B1 B cells in the first 3 days of a primary response 
to generate an enormous thymus-independent (TI) IgM-antibody response to 
particulate antigens, such as streptococcus pneumoniae (175). Activated DCs and 
peritoneal macrophages produce B cell-activating factor (BAFF), which additionally 
stimulates B cells and thereby sustain this response (176). Another example of TI 
responses is the IgA response to intestinal flora. Without T cell help or organized 
lymphoid structures, B1 B cells produce large amounts of intestinal IgA in the 
presence of intestinal microflora, which is specific for cell wall antigens of commensal 
bacteria (177). 
There are other innate mechanisms existing which are involved in TI antibody 
responses and are associated to complement activation. BCR signal transduction is 
facilitated by the complement protein fragment C3d which binds to the microbial 
surface and simultaneously to its receptor CD21 expressed on B cells and finally 
results in enhancement of the cellular responses (178). C4-binding protein (C4BP), a 
protein that binds the complement protein fragments C4b and C3b, is able to engage 
CD40 on B cells thus imitating a T helper cell (179). 
 
5.4.3 TLRs in thymus-dependent B cell responses 
DCs activated by adjuvants or TLR agonists prime T helper cells by presenting the 
antigen on MHC class II molecules. Subsequently, those helper T cells stimulate B 
cells. Antibody responses to protein antigens need this interaction of B cells and T 
helper cells. However, Pasare and Medzhitov studied TLR engagement on B cells in 
response to protein antigens in mice in which MyD88 deficiency was restricted to B 
cells (180). Human serum albumin and LPS primed T helper cells were injected into 
these mice, however, an induction of an optimal antibody response failed to appear. 
TLR-stimulation on B cells was essential for IgG2 responses and, to a lesser extent, 
for IgM and IgG1 responses, while IgE responses were TLR-independent. Those 
results show that direct stimulation of TLRs on B cells increases and modulates the 
antibody response to a protein antigen even when the TLR agonist is not bound to 
the BCR (180). 
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5.4.4 TLRs on human naive and memory B cells 
Human naive B cells express only low levels of TLRs unless they are stimulated 
through the BCR (181,182). In a study using highly purified human naive B cells 
(183), it has been shown that in addition to BCR stimulation and cognate T cell help, 
direct triggering of TLRs on responding B cells was required to induce efficient B cell 
proliferation, isotype switch to IgG and IgA, and differentiation to antibody-secreting 
cells (184). The coupling that only BCR-stimulated naive B cells express TLRs and 
therefore can respond to innate signals renders the human immune system highly 
specific. Human memory B cells constitutively express TLR2, TLR6, TLR7, TLR9 and 
TLR10, and stimulation of those TLRs leads to proliferation and differentiation to 
antibody-secreting plasma cells (181,182,185).  
 
5.4.5 TLRs and class switch recombination 
There is some evidence that TLR stimulation on B cells influences isotype switching. 
In mice, class switching to the pathogenetic IgG2a and IgG2b autoantibodies 
requires TLR9 and MyD88, however, development of IgM autoantibodies does not 
(186). Moreover, TLR9-triggering, but not TLR4-triggering, upregulates T-bet 
expression in B cells and induces IgG2a while it decreases IgG1 and IgE production 
(187,188). The CpG-induced inhibition of IgG1 and IgE is T-bet-independent and 
might be mediated by induction of B-cell lymphoma protein 6 (Bcl-6) or inhibitor of 
DNA binding protein 2 (Id2) (189). In human B cells, activation of TLR9 by CpG-DNA 
initiates germline immunoglobulin heavy chain constant region Cg1, Cg2 and Cg3 
gene transcription, in association with IL-10 (190). In addition to directly acting on B 
cells, TLR agonists can also indirectly influence B cell differentiation and isotype 
switching via activation of DCs. Activated pDCs release IFN-α and IL-6, which are 
responsible for the differentiation of plasma cells (191) and induce expression of 
BAFF and a proliferation-inducing ligand (APRIL) on conventional DCs. BAFF and 
APRIL trigger CD40-independent class switch recombination very efficiently (192). 
mDCs triggered by synergizing TLR stimuli (193) produce IL-12, which 
subsequentially activates human naive B cells to differentiate into IgM producing 
plasma cells (194). In a recent study, retinoic acid synergized with gut-associated 
lymphoid tissue (GALT)-DC-derived IL-6 or IL-5 to induce IgA secretion (195), 
however, the role of TLRs in this system remains to be elucidated. Originally, it has 
been tought that isotype switch was restricted to germinal centers of secondary 
lymphoid organs, but in several studies it has been shown to take place also outside 
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organized lymphoid tissues. In mice, IgM+ lymphocytes in the gut lamina propria 
switch in situ to IgA (196). In humans, IgE switching has been observed in the nasal 
mucosa of allergic rhinitis patients (197). In another study, activation of TLR3 on 
reticular epithelial cells of human tonsils led to the production of BAFF and IL-10, 
which enhance class switching and IgG and IgA secretion in naive B cells. This 
response was amplified by thymic stromal lymphopoietin (TSLP) but inhibited by 
secretory leukocyte protease inhibitor (SLPI) (198).  
 
5.4.6 TLRs and regulatory T cells  
TLRs are also expressed on regulatory T cells. Wang et al. demonstrated that a 
direct stimulation of TLR8 on human Treg cells can reverse Treg cell function (199). 
TLR8 ligand-stimulated Treg cells were transfered into tumor-bearing mice resulting 
in a dramatic enhancement of the anti-tumor immunity. Another study showed that in 
TLR2-/- mice, the number of CD4+CD25+ Treg cells is significantly reduced compared 
to wildtype mice (200). Surprisingly, combined stimulation of TCR and TLR2 on 
Tregs enhanced Treg proliferation in vitro and in vivo and resulted in a temporal loss 
of the suppressive Treg phenotype in vitro (200). Hence, TLR-mediated regulation of 
Treg might be linked to the onset and severity of allergic diseases. 
 
5.4.7 TLRs in allergic disease 
The enhanced prevalence of allergic diseases in the industrialized countries has 
been explained by the hygiene hypothesis. Bacterial and viral infections during early 
childhood are believed to direct the maturing immune system towards Th1, which 
counterregulates pro-allergic Th2 responses. Increased hygiene and a reduced 
microbial environment result in low stimulation of TLRs and subsequently in weak 
Th1 imprinting. This leads to unrestricted Th2 responses that presumably provoke 
allergies (140). This hypothesis is supported by the observation that viral infections 
such as hepatitis A, measles and tuberculosis are negatively associated with the 
incidence of allergic diseases (201). Children, who are growing up in a farm and 
have a decreased risk of developing allergies, have an enhanced expression of 
TLR2mRNA. Therefore, TLR2 might modulates the development of allergic diseases 
(202). Furthermore, it has been identified that polymorphisms in the TLR2 gene are 
associated to the susceptibility to develop allergic diseases (203,204). In an 
epidemiological study, also the TLR4 signaling pathway has been shown to play a 
role in the development of allergies. In homes of allergen-sensitized infants, house 
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dust endotoxin levels were lower compared to houses of non-sensitized infants. 
Therefore, the idea arose, that indoor exposure may protect against allergen 
sensitization (205). LPS exposure and atopy rates in farmers’ family members 
correlated inversely supporting this hypothesis (206). Moreover, polymorphisms of 
CD14, a LPS coreceptor for TLR4, influenced the severity of atopy (207). The 
knowledge about the association of other TLRs and the development and severity of 
allergic diseases is little, but for intervention and treatment of allergic disease, 
several TLRs have been used as targets. 
 
 
5.5  Allergen-specific immunotherapy 
5.5.1 Conventional immunotherapy 
More than 25% of the population in industrialized countries shows IgE-mediated 
hypersensitivity, which is the most common form of allergy (208). Various 
environmental proteins, known as allergens, elicit an allergic response. Allergic 
rhinitis, allergic asthma, food allergy, allergic skin inflammation, ocular allergy and 
anaphylaxis are clinical manifestations of allergic responses. Allergic inflammation 
and reactions to allergens can be either local, like in allergic rhinitis or allergic 
asthma, or systemic, like in anaphylaxis. 
The etiology of allergic diseases is very complex and several factors, 
including genetic susceptibility, route of exposure, dose and structural characteristics 
of the allergen have an impact (209). Antihistamines, antileukotrienes, β2-adrenergic 
receptor antagonists and corticosteroids can temporarily suppress the mediators and 
immune cells and thus alleviate the symptoms of IgE-mediated allergic reactions 
(92,210,211). Allergen-specific immunotherapy (SIT) is the only treatment so far 
which leads to long-term recovery and specifically reestablishes a normal immunity 
against allergens. This treatment involves repeated, mostly subcutaneous, 
administration of the allergen, and has been applied most efficiently to insect venom 
allergy and allergic rhinitis (212-214). An increase of IgG4 as well as a decrease in 
the number of mast cells and eosinophils, which are responsible for the release of 
mediators (88,215-217) can be observed in a successful allergen-SIT. Furthermore, 
IL-4 and IL-5 production by CD4+ T cells was decreased during allergen-SIT 
(214,218). In SIT to bee venom, wasp venom, grass pollen and house dust mite 
(HDM), a change from a Th2 cytokine pattern towards a Th1 phenotype with 
increased IFN-γ production was observed (219,220). Importantly, the induction of a 
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tolerant state in peripheral T cells seems to be a crucial step during allergen-SIT 
(98,221,222). Autocrine action of IL-10 and TGF-β increasingly produced by the 
antigen-specific T cells leads to T cell tolerance (98,221). These cells express CD4 
and CD25 and could be both, inducible Tr1 cells, which have upregulated CD25 or 
naturally occurring CD4+CD25+ Treg cells that produce suppressive cytokines (223). 
CD4+CD25+ Treg cells from atopic donors have been shown to have a reduced 
capability to suppress the proliferation of CD4+CD25- T cells (224). Thus, 
upregulation of CD4+CD25+ Treg cells probably plays an important role in allergen-
SIT. Depending on the cytokine that is present in the tissue microenvironment, 
tolerized T cells can be reactivated and start to produce either Th1 or Th2 cytokines. 
Therefore, allergen-SIT might be directed towards successful or unsuccessful 
treatment (225). During the early phase of SIT, serum levels of both specific IgG4 
and IgE increased. However, the antigen-specific IgG4 increase was stronger and 
thus, the ratio of specific IgE to IgG4 decreased by 10- to 100-fold (225). The 
development of such a specific isotype ratio could be observed in SIT against various 
allergies. Furthermore, during SIT, increasing amounts of IL-10 are produced. IL-10 
has been shown to suppress both total- and allergenspecific IgE, but to increase 
IgG4 production (98,129,226). In healthy individuals, response to Der p1 showed 
enhanced specific IgA and IgG4, low amounts of IgG1 and nearly undetectable IgE 
antibodies in serum (222). Although antigen-specific IgE levels did not decrease 
significantly after 70 days of treatment during HDM SIT, antigen-specific IgA, IgG1 
and IgG4 showed a significant rise (222). Additionally, the increase of specific IgA 
and IgG4 in serum coincided with elevated concentrations of TGF-β and IL-10, 
respectively (98,222,227). 
The fundamental mechanisms occurring during allergen-SIT are continuously 
being clarified. The very early effects comprise mast cell and basophil 
desensitization, intermediate effects are characterized by changes in allergen-
specific T cells and late effects imply B cells (228), IgE as well as mast cells, 
basophils and eosinophils. Several years of SIT are needed to observe a decrease in 
IgE antibody levels and IgE-mediated skin sensitivity, but interestingly, most allergic 
individuals show a protective response against bee-stings already at an early stage 
of bee venom-SIT. One explanation for this is that effector cells of allergic 
inflammation, such as mast cells, basophils and eosinophils are dependent on T cell 
cytokines for priming, activity and survival (229,230), which are not sufficiently 
available because of suppressed Th2 and Th1 cells. The SIT efficiently enhances the 
thresholds for mast cell and basophil activation and simultaneously, reduces 
histamine release mediated by IgE (231,232). Moreover, IL-10 reduces the secretion 
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of proinflammatory cytokines from mast cells (233), down-regulates eosinophil 
activity and prevents IL-5 production by human resting Th0 and Th2 cells (234). 
Besides, it inhibits endogenous granulocyte monocyte colony-stimulating factor (GM-
CSF) production and CD40 expression by activated eosinophils and induces 
eosinophil cell death (235). 
 
5.5.2 Current developments in specific immunotherapy 
Peptide immunotherapy (PIT) is another attractive approach for safe SIT. Such 
allergen peptides are short and consist of either original sequences or have some 
altered amino acid substitutions, but they still contain the linear T cell epitopes, 
however, not the three-dimensional B cell epitopes. Therefore, IgE cross-linking, 
which can induce anaphylaxis, is inhibited (236). Several years ago, application of 
PIT using exact T cell epitope peptides from the major bee venom allergen PLA2 was 
very successful (237). During this study, development of specific T cell tolerance and 
a decrease in the specific IgE:IgG4 ratio could be observed. Various allergen-
peptides are now available for PIT, including the latex allergen Hev b 6.01, the cat 
allergen Fel d 1, the house dust mite allergen Der p 1 and birch pollen allergen Bet v 
1 (238-241). Patients undergoing PIT usually tolerate this treatment very well, 
because peptide vaccination does not induce IgE responses. In contrast, Th2 
responses are reduced and simultaneously, IL-10 secretion is enhanced, suggesting 
an increase of Tr1 cells. One disadvantage of PIT, however, is the limited 
applicability, because due to the very individual MHC class II-mediated antigen 
presentation, not all patients are able to respond to the same peptides. 
The usage of recombinant hybrid allergen proteins could be another useful 
method for SIT (242,243). In a single molecule, several T cell epitopes are linked 
together. Therefore, the immunogenicity of the components is increased compared to 
separate molecules. In human skin-prick tests, a hybrid allergen protein consisting of 
three major bee venom allergens showed to be extremely hypoallergenic, and in a 
mouse model, it could also prevent allergic sensitization to bee venom (242).  
Vaccination with allergen-encoding DNA has been proposed as a further strategy for 
SIT (244,245). This method enhanced allergen-specific Th1 cell responses and, 
when administered prophylactically in mouse models, prevented allergic 
sensitization. The disadvantage however, is that transfected cells produce allergen 
systemically, thereby enhancing the potential of anaphylaxis (246). However DNA 
encoding hypoallergenic allergens could reduce allergenicity. 
Sublingual administration of allergen is another approach for SIT and 
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immediate swallowing of allergen as a therapy has been used since 1927. During 
sublingual immuno therapy (SLIT) the allergen is captured by Langerhans cells within 
the oral mucosa. Thereafter, these cells mature and migrate to proximal draining 
lymph nodes, where the synthesis of blocking IgG antibodies and the induction of 
Treg cells is started (247,248). Sublingual immunotherapy (SLIT) is clinically 
efficacious, but so far, the treatment effect is only about half of that achieved with 
subcutaneous SIT (249). 
 
 
5.6  Histamine in allergic inflammation 
5.6.1 Histamine 
Histamine, 2-(4-imodazole)-ethylamine, is mainly produced by mast cells and 
basophils, gastric enterochromaffin-like cells, platelets and histaminergic neurons. 
But also in other cells of the immune system like monocytes/macrophages, DCs, 
neutrophils and T and B cells, high histidine decarboxylase activity is observed. 
However, although these cells do not store histamine, they can produce high 
amounts of this mediator, which is secreted immediately after synthesis (250-253). 
Released from mast cells and basophils, histamine triggers acute symptoms like 
rhinitis, bronchospasm, cramping, diarrhea or cutaneous wheal and flare responses 
due to its very rapid activity on vascular endothelium and bronchial and smooth 
muscle cells. However, it influences both normal human physiology as well as 
various pathologies. It is involved in the cell differentiation and proliferation, 
embryonic development, hematopoiesis, wound healing and regeneration (254-258), 
but has also an influence in the central nervous system on cognition and memory, 
regulation of the sleep/wake cycle, energy and endocrine homeostasis (259-261). 
Furthermore, histamine exhibits all the properties of a classical leucocyte 
chemoattractant, including actin polymerization, mobilization of intracellular calcium, 
alteration in cell shape, and up-regulation of adhesion molecule expression. 
 
5.6.2 Histamine receptors 
So far, there are four types of histamine receptors (HRs) known that belong to the G-
protein-coupled receptor family: HR1, HR2, HR3 and HR4 (Table 4).  They are seven 
transmembrane proteins that use G proteins and intracellular second messengers to 
transduce extracellular signals (262,263). The four HRs have different Ki values 
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ranging from 2-10 µM for the HR1 and HR2 to 5-10 nM for the HR3 and HR4 
(264,265). Triggering of the Gq/11-coupled HR1 leads to many of the symptoms of 
allergic disease in the skin, nose, and lower airways. 
HR1 and HR2 are expressed on numerous cells, including airway and 
vascular smooth muscle cells, hepatocytes, chondrocytes, nerve cells, endothelial 
cells, DCs, monocytes, neutrophils, T and B cells (266-268). Histamine enhances the 
secretion of proinflammatory cytokines such as IL-1α, IL-1β, IL-6 as well as 
chemokines such as regulated activation (RANTES) or IL-8, in several cell types and 
local tissues and thus contributes to the progression of allergic inflammation (269-
272). HR1 and HR2 are also expressed on endothelial cells, and via HR1, histamine 
infusion leads to increased expression of adhesion molecules such as intracellular 
adhesion molecule (ICAM-1), vascular cellular adhesion molecule (VCAM-1) and P-
selectin (273-275). The expression of histamine receptors on endothelial cells is 
regulated by the ligand itself (276). 
Granulocyte accumulation in tissues is regulated by histamine in distinct 
ways. Allergen-induced recruitment of eosinophils in the skin, nose and airways can 
be inhibited by HR1 antagonists (277). Depending on the concentration of histamine, 
eosinophil migration varies. High concentrations inhibit eosinophil chemotaxis via 
HR2, low concentrations enhance eosinophil chemotaxis via HR1 (278). In addition, 
histamine inhibits neutrophil chemotaxis, activation, superoxide formation and 
degranulation due to HR2-triggering (279). 
HR3 is expressed in the central and peripheral nervous systems where it 
functions as a pre-synaptic receptor controlling the release of histamine and other 
neurotransmitters. The control of mast cells by histamine acting on HR3 involves 
neuropeptide-containing nerves and might be related to a local neuron-mast cell 
feedback loop controlling neurogenic inflammation (280). In case of dysregulation of 
this feedback loop, excessive inflammatory responses appear which suggests that 
HR4 agonists may represent a novel therapeutic approach.  
HR4 is coupled to protein Gi/o, inhibiting forskolin-induced cAMP formation like 
HR3 (263). HR4 is highly expressed in the bone marrow and on peripheral 
hematopoietic cells, neutrophils, eosinophils and T cells. Moderate expression of 
HR4 is found in spleen, thymus, lung, small intestine, colon, and heart (263). Both 
basophils and mast cells express HR4mRNA (281). Recruitment of inflammatory 
cells, particularly eosinophils and mast cells, at sites of allergic inflammation is 
promoted by stimulation of HR4 (282). The presently available HR3 ligands can also 
be bound by the HR4, due to the high homology between the two receptors (263). 
Recently, it has been shown that the HR1/HR2 antagonist doxepin and the HR1 
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antagonist cinnarizine and promethazine have high affinity to the HR4. Administration 
of HR4 antagonists could eliminate HR4-mediated chronic inflammatory effects of 
histamine, and treatments with combinations of HR4 and HR1 antagonists may be 
very useful. 
 
 
Table 4. Histamine receptors 
 H1 receptor H2 receptor H3 receptor H4 receptor 
Expression Nerve cells, airway and 
vascular smooth 
muscles, hepatocytes, 
chondrocyes, 
endothelial cells, 
neutrophils, eosinophils, 
monocytes, DC, T and 
B cells 
Nerve cells, airway and 
vascular smooth 
muscles, hepatocytes, 
chondrocyes, 
endothelial cells, 
neutrophils, eosinophils, 
monocytes, DC, T and 
B cells 
Histaminergic neurons, 
eosinophils, DC, 
monocytes; low 
expression in peripheral 
tissues 
High expression on 
bone marrow and 
peripheral 
hematopoietic cells, 
eosinophils, neutrophils, 
DC, T cells, basophils, 
mast cells; 
Low expression  in 
nerve cells, hepatocytes 
peripheral tissues, 
spleen, thymus, lung, 
small intestine, colon 
and heart 
Intracellular 
signals 
Ca2+, cGMP, 
phospholipase D, 
phospholipase A2, 
NFκB 
Adenylate cyclase, 
cAMP, c-Fos, c-Jun, 
PKC, p70S6K 
Ca2+, MAP kinase, 
inhibition of cAMP 
Ca2+, inhibition of cAMP 
Activities of 
histamine in 
allergic 
inflammation 
and immune 
modulation 
Release of histamine 
and other mediators ↑ 
Adhesion molecule 
epression ↑ 
Chemotaxis of 
eosinophils and 
neutrophils ↑ 
Antigen-presenting 
capacitiy ↑ 
Co-stimulatory activity 
on B cells ↑ 
Cellular (Th1) immunity, 
IFN-γ, autoimmunity ↑ 
 
Humoral immunity ↓ 
IgE production ↓ 
IL-10 production ↑ 
Development of Th2  
and tolerance-inducing 
DCs ↑ 
Humoral immunity ↑ 
Suppression of Th2 
cells and cytokines ↑ 
 
Chemotaxis of 
eosinophils and 
neutrophils ↓ 
Production of IL-12 by 
DCs ↓ 
Cellular immunity ↓ 
 
Plays a role in allergy, 
autoimmunity, graft 
rejection 
Proinflammatory activity 
and antigen-presenting 
capacitiy ↑ 
 
Involved in control of 
neurogenic 
inflammation by neuron-
mast cell feedback loop 
  
Eosinophil chemotaxis ↑ 
 
IL-16 production ↑ (HR2 
is also involved) 
Antagonists > 40; including 
diphenhydramine, 
cetirizine, desloratadine, 
fexofenadine, loratadine 
Cimetidine, famotidine, 
nizatidine, ranitidine 
 
None None 
Adapted from Akdis C.A. et al., European Journal of Pharmacology. 2006; 533: 69-76. 
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5.6.3 Immunoregulatory effects of histamine on APCs 
Immature and mature DCs express all four HRs (283-285) and during the 
differentiation of monocytes to mDCs, activation of HR1 and HR3 induces antigen-
presentation capacity and proinflammatory cytokine production as well as Th1 
priming activity. HR2, however, suppresses the antigen-presentation capacity, 
enhances production of IL-10 and induces IL-10-secreting T cells (Fig. 4) 
(89,286,287). 
In monocytes that have been activated by TLR triggering, histamine 
decreases the production of proinflammatory IL-1-like activity, TNF-α, IL-12 and IL-18 
but simultaneously, enhances IL-10 secretion via HR2 stimulation (272,287-290). 
Moreover, on human monocytes, histamine down-regulates CD14 expression 
through HR2 (291). In immature DCs, histamine induces intracellular Ca2+ flux, actin 
polymerization, and chemotaxis due to stimulation of HR1 and HR3, but when DCs 
mature, these responses disappear and histamine induces intracellular cAMP levels 
and IL-10 secretion, while IL-12 production is suppressed via HR2 (89). Human 
mDCs express both HR1 and HR2 and can induce CD86 expression by histamine, 
but surprisingly, human epidermal Langerhans cells (LC) express neither HR1 nor 
HR2 receptors, probably because of the effect of TGF-β (292), which has been 
identified as a mandatory factor for the development of LCs, but not for that of 
interstitial/dermal DCs (293). Soga et al. showed that histamine prevents monocytic 
apoptosis via HR2 and cAMP pathway and that this phenomenon results partially 
from the histamine-induced endogenous production of IL-10 (294). In chronic allergic 
disorder like asthma or atopic dermatitis, HR2 signals prolong the lifespan of 
monocytes and the infiltration to the site of inflammation. 
HR1 antagonists inhibit allergen-induced inflammatory cell accumulation in 
the skin, nose and airways. A possible mechanism for HR1 antagonists might be the 
downregulation of NF-κB, a potent transcription factor, which plays a role in initiating 
inflammation by inducing proinflammatory cytokines (295). Furthermore, HR1 
antagonists decreased the amounts of proinflammatory cytokines, mediators (e.g. 
histamine, leukotrienes, prostaglandin), cells (e.g. neutrophils, eosinophils), cell 
adhesion molecules (e.g. intercellular and vascular cell adhesion molecules) in the 
lavage fluid of asthmatic patients. In a murine model of allergen-induced airway 
inflammation and hyperresponsiveness, fexofenadine diminished a Th2-like 
response by decreasing secretion of IL-4, IL-5, allergen-specific IgE and eosinophilia 
in lung tissue and bronchoalveolar lavage fluid (296). Therefore, HR1 antagonists, 
which have weaker anti-inflammatory effects than corticosteroids, may modulate the 
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balance between Th1, Th2 and Tr1 cells and suppress the accumulation of 
inflammatory cells. 
 
5.6.4 Effects of histamine on Th1 and Th2 cells 
Th1 cells express HR1 predominantly, but not exclusively, whereas Th2 cells show 
higher expression of HR2. Due to different intracellular signaling pathways, activation 
of HR1 elicits Th1 responses, while triggering of HR2 decreases both Th1- and Th2-
responses (92). In mice, deletion of HR1 leads to decreased IFN-γ production and to 
enhanced secretion of IL-4 and IL-13. Deletion of HR2 results in upregulation of both 
Th1 and Th2 cytokines. In another study, it has been shown that histamine induced 
IL-10 secretion via HR2 (90). Increased IL-10 production by histamine in both DCs 
and T cells might be an important regulatory mechanism for the control of 
inflammation (Fig. 4).  
 
Figure 4. Histamine influences the inflammatory functions of T cells and APCs 
in lymphatic organs and subepithelial tissues. DCs express all four HRs, 
whereas Th1 cells express predominantly HR1. Stimulation of HR1 on Th1 cells 
induces their proliferation and IFN-γ production. Th2 cells show a higher expression 
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of HR2. Histamine released from effector cells suppresses both Th1 and Th2 
responses and induces IL-10 production in DCs, Treg and Th2 cells via HR2. IL-10-
secreting DCs contribute to Treg cell generation. Furthermore, HR2 potentiates the 
effect of TGF-β (solid black arrows: activation; dotted red arrows: suppression). 
Adapted from Jutel et al., 2006, Allergy, 61, 796-807. 
 
5.6.5 Role of histamine in T cell tolerance to allergens 
During SIT, the peripheral tolerance is also influenced by histamine in several ways. 
Histamine induces the IL-10 production by DCs (89) and by Th2 cells (90). In 
addition, it increases the suppressive activity of TGF-β on T cells (91). These effects 
are all mediated via activation of HR2 (92), which seems to represent an essential 
receptor that plays an important role in induction of peripheral tolerance or active 
suppression of inflammatory immune responses. 
Because of their ability to modify immune responses, HR2 antagonists have 
attracted great attention. Cimetidine shows a stimulatory effect on the immune 
system, probably by binding to the receptors on the T cell subsets and thereby 
preventing HR2-induced immune suppression (297). A beneficial effect of cimetidine 
has been observed when administered as supplement to surgical excision in patients 
with colorectal, gastric, breast or ovarian cancers, and melanoma (298).  
 
5.6.6 Regulation of antibody isotypes by histamine 
HR1 signaling seems also to play an important role in responses triggered from 
BCRs. In mice, the proliferation of B cells stimulated with anti-IgM is enhanced by 
histamine, whereas in HR1-deleted mice, antibody production against a T cell-
independent antigen TNP-Ficoll is reduced (280).  However, in response to T cell-
dependent antigens, such as ovalbumin, HR1-deleted mice produced high OVA-
specific IgG1 and IgE compared to wild-type mice (280). In HR2-deleted mice, 
decreased serum levels of OVA-specific IgE was observed compared to wild-type 
and HR1-deleted mice. Although the IL-4 and IL-13 production by T cells in HR2-
deficient mice increased, OVA-specific IgE was suppressed due to highly enhanced 
IFN-γ. Thus these findings suggest that HR1 and the related Th1 response play an 
important role in the suppression of humoral immune responses. 
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6 Results 
6.1 Distinct regulation of IgE, IgG4 and IgA by T regulatory 
cells and toll-like receptors 
 
F. Meiler, S. Klunker, M. Zimmermann, C. A. Akdis, M. Akdis 
 
Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland 
 
 
 
 
Key words: B cells, immunoglobulins, regulatory T cells, IL-10, toll-like receptors  
 
 
Corresponding author:  
 
Mübeccel Akdis  
Swiss Institute of Allergy and Asthma Research (SIAF)  
Obere Strasse 22  
7270 Davos Platz, Switzerland  
Phone: +41 81 410 08 48 
Fax: +41 81 410 08 40 
E-mail: akdism@siaf.uzh.ch 
 
 
 
 
Submitted to Allergy 
 
Results
 
 49 
 
Background: Allergic diseases are characterized by the activation of the immune 
system and formation of immunoglobulin (Ig) E antibodies against normally 
innocuous environmental antigens, whereas IgG4 and IgA represent non-
inflammatory and blocking antibody isotypes. The T helper 2 (Th2) cells induce and 
T regulatory (Treg) cells suppress several features of allergic inflammation. Our aim 
was to investigate the role of allergen-specific T regulatory type 1 (Tr1) cells and 
CD4+CD25+ Treg cells and toll-like receptors (TLRs) on IgE, IgG4 and IgA 
production. 
Methods: Germline or productive Ig-transcripts are determined by real-time RT-
PCR, secreted Igs are measured by ELISA and the frequency of Ig-producing 
plasma cells is investigated by ELISPOT. Circulating CD4+CD25+ Treg cells and 
allergen-specific Tr1 cells are used. 
Results: Both allergen-specific, IL-10-secreting Tr1 cells and CD4+CD25+ Treg cells 
from healthy individuals induced IgG4 and suppressed IgE production in peripheral 
blood mononuclear cells (PBMC) and purified B cell cultures. In contrast, induction of 
IgA production is independent of T cell help and the role of Tr1 or Treg cells is very 
limited, whereas it was highly induced by direct B cell activation via TLR7 and 9.  
Conclusions: These data suggest that T regulatory cells may contribute to the 
suppression of allergic diseases by suppression of IgE and induction of IgG4, 
whereas IgA production is enhanced by B cell activation via TLR7 and TLR9.  
 
Key words: B cells, immunoglobulins, regulatory T cells, IL-10, toll-like receptors  
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Introduction 
The physiopathology of allergic immune responses is complex and has been shown 
to be regulated by multiple factors. Hallmark of the allergic immune response is the 
development of allergen-specific Th2 cells and their cytokines IL-4 and IL-13, which 
are responsible for IgE and IgG4 production by B cells (299). The type and amount 
of antibodies produced vary according to the type of allergen/antigen, involvement of 
T cells, prior history of antigen exposure, and anatomic site. Class switch 
recombination in B cells requires two signals. The first is delivered by cytokines, 
which target specific CH genes for transcription, the second is delivered in the case 
of T-dependent antigens by interaction of CD40 on B cells with its ligand CD40L on 
activated T cells (35).  
Patients suffering from asthma, allergic rhinitis and atopic dermatitis, have 
elevated serum levels of both total IgE and of IgE that is specific for the allergens 
that drive these diseases (300,301). The induction of a tolerant state in peripheral T 
cells represents an essential step in healthy immune response to allergens in 
sensitized individuals (87). Peripheral T cell tolerance observed in healthy individuals 
and during allergen-specific immunotherapy is characterized mainly by generation of 
allergen-specific Tr1 cells and increase in allergen-specific suppressive capacity of 
whole CD4+CD25+ T cells (98,222,224). This is accompanied by a significant 
increase in allergen-specific IgG4 and in some cases IgA and a decrease in IgE in 
the late stage of the treatment (222,301,302). Moreover, it has been shown that IL-
10 decreased IL-4-induced IgE switching but augments IL-4-induced γ4 transcript 
expression and IgG4 production (129). 
 Along with CD4 and CD25 expression, Treg cells are also associated with 
the transcription factor Foxp3 (303). Various autoimmune diseases such as arthritis, 
diabetes and X-linked immune dysregulation, polyendocrinopathy and enteropathy 
syndrome (IPEX) with hyper-IgE may develop spontaneously when CD4+CD25+ 
Treg cells are eliminated, suggesting a role for the control of IgE production (304). 
Immunoglobulin isotype switch, which was originally thought to be restricted to 
germinal centers of secondary lymphoid organs, can occur outside organized 
lymphoid tissues. IgE switch has been shown to take place in the nasal and 
bronchial mucosa of allergic rhinitis and asthma patients (197,305,306). 
Human memory B cells express TLR2, TLR6, TLR7, TLR9 and TLR10, but 
not TLR3 and TLR4 (181,182). TLR7 and TLR9 recognize nucleic acids of microbial 
as well as of endogenous origin (307) and they are both present in endosomal 
compartments. As B cells are poorly phagocytic, but can efficiently internalize 
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molecules that bind to the B-cell receptor (BCR), they can target RNA- or DNA-
containing molecular complexes, which are capable of binding to the BCR, to TLR7 
or TLR9 in the endosomal compartment. Consequently, TLR agonists can directly 
activate human memory, but not naive B cells and it has been suggested that this 
selective responsiveness may be a mechanism to maintain serological memory 
(307).  
In the present study, we demonstrate that T regulatory cells regulate antibody 
isotypes, which may contribute to the suppression of inflammatory diseases by the 
induction of IgG4 and by the suppression of IgE. However, production of IgA is not 
influenced by regulatory T cells, but is strongly dependent on the innate immune 
system, particularly TLR7 and TLR9 activation of B cells. 
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Methods 
 
Medium, antigen, cytokines and TLR-agonists 
The medium used for 5-day-cultures was RPMI 1640 supplemented as previously 
described (87). The medium used for 12-day-cultures was additionally supplemented 
by 40 µg/ml of transferrin and 4 µg/ml of insulin (both from Sigma, Buchs, 
Switzerland). Recombinant Dermatophagoides pteronyssinus group 1 (Der p 1) of 
house dust mite (Allergopharma, Reinbek, Germany) and phospholipase A2 of bee 
venom (PLA, Sigma Chem. Co.)  were used as allergens. They did not contain 
detectable amounts of LPS and were 99% pure. Recombinant human IL-4 was from 
Novartis, Basel, Switzerland, IL-10 from PeproTech, London, UK and anti-human IL-
10 receptor from ATCC, Middlesex, UK. Soluble CD40L ligand (sCD40L) was 
produced from the transfected cell line 8-40-1, originally generated by Dr. P. Lane 
(Birmingham, UK) and cultured for 3 d in CG medium (Vitromex GmbH, Vilshofen, 
Germany) and standardized according to highest IgE inducing capacity after 12 d 
culture of PBMC co-stimulated with 50 ng/ml of IL-4 (308). Supernatants obtained 
from the corresponding untransfected cell line J558L (kindly provided by Dr. M. Reth, 
University of Freiburg, Freiburg, Germany) were used as control. 
Following TLR agonists were used: Pam3-Cys-Ser-(Lys)4 for TLR2 
(Calbiochem AG, Laufelfingen, Switzerland), poly(I:C) for TLR3 (Amersham 
Biosciences, Lausanne, Switzerland), E. Coli derived lipopolysaccharide for TLR4 
(Sigma, Buchs, Switzerland), flagellin for TLR5 (Calbiochem AG), 3M-001 for TLR7 
(3M Pharmaceuticals, Minneapolis, USA), 3M-002 for TLR8 (3M Pharmaceuticals), 
CpG2006 for TLR9 (Microsynth GmbH, Balgach, Switzerland).  
 
Purification of B cells, Tr1 and CD4+CD25+ Treg cells 
PBMC were isolated by Ficoll (Seromed, Vienna, Austria) density gradient 
centrifugation from peripheral venous blood of healthy donors. B cells were isolated 
by depleting non-B cells by using a cocktail of biotin-conjugated antibodies against 
CD2, CD14, CD16, CD36, CD43 and CD235a and anti-biotin microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The purity of B cells was more than 95%.  
For the isolation of IL-10-secreting cells, PBMC were stimulated with 0.3 
µmol/L antigen in 5 ml of medium in six-well plates (Becton Dickinson, Franklin 
Lakes, NJ, USA) (87). After 12 h of stimulation in humidified 5% CO2, cells were 
harvested and labeled with anti–IL-10/CD45 Ab–Ab conjugates (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The cells were diluted with 37°C warm medium to a 
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final concentration of 106 cells/ml and allowed to secrete and capture IL-10. After 
capturing the secreted cytokine on their surface, cells were stained with PE-
conjugated anti–IL-10 mAb. The cells were washed and resuspended in PBS, 
containing 0.5% bovine serum albumin (BSA) and 2 mmol/L EDTA, and magnetically 
labeled with anti-PE microbeads. After another washing step, labeled cells were 
purified (AutoMacs, Miltenyi Biotec, Bergisch Gladbach, Germany).  
Purification of CD4+CD25+ Treg cells was performed in a two-step procedure. 
First, non-CD4+ cells were depleted with a cocktail of biotin-conjugated antibodies 
against CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and glycophorin A 
and anti-biotin microbeads. In the second step, CD4+CD25+ T cells were directly 
labeled with anti-CD25 microbeads and isolated by positive selection from the pre-
enriched CD4+ T cell fraction. The cells were counterstained by FITC-labeled anti-
CD4 and PE-labeled anti-CD25 mAb (Beckman Coulter, Fullerton, CA, USA) and 
analyzed in a flow cytometer (Epics XL; Beckman Coulter). The purity of CD4+CD25+ 
Treg cells was between 92.5% and 96.9%. High Foxp3 expression in CD4+CD25+ 
cells, purified by this method, has been previously reported (119). 
 
Cell cultures  
PBMC or pure B cells from non-allergic and healthy donors were incubated at 37°C 
either for 5 days (RT-PCR) in cRPMI or for 12 days (ELISA and ELISPOT) in insulin 
and transferrin supplemented cRPMI with IL-10-secreting Tr1 or CD4+CD25+/- cells. 
After optimization of cell number, 2.5 x 106 PBMC were cultured with 4’000 isolated 
IL-10-secreting, Der p 1-specific T cells or with 33’000 CD4+CD25+/- T cells in 6-well-
plates. 4’000 Der p 1-specific, IL-10-secreting cells or 11’000 CD4+CD25+/- T cells 
were co-cultured with 200’000 purified B cells in 96-well-plates.  
 
Determination of IgE, IgG4 and IgA by real-time PCR, ELISA and ELISPOT 
Refer to Methods in the Supplementary material. 
 
Statistical Analysis 
Statistical analysis was performed using the paired Student’s t-test and the Wilcoxon 
Matched Pairs Signed Ranks test. 
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Results 
 
IL-10-secreting Tr1 cells suppress IgE and induce IgG4 production  
Antibody synthesis and secretion in response to protein antigens are stimulated by 
CD40-mediated signals and B cell-activating cytokines expressed by T cells. 
Therefore, it was hypothesized that allergen-specific, IL-10-secreting Tr1 cells, which 
represent the dominant subset specific for common environmental allergens in 
healthy individuals, may also have an effect on Ig regulation. In the following 
experiments, we used IL-4 and sCD40L to induce IgE and IgG4, because IL-10-
secreting Tr1 cells and IL-10 alone induced only very little IgG4 and no IgE (Fig. S1 
in the Supplementary material). Der p 1-specific, IL-10-secreting, Tr1 cells are 
isolated from PBMC of healthy individuals and their role on IgE and IgG4 production 
is investigated. As shown in Fig. 5A, Tr1 cells suppressed germline ε transcript 
expression and simultaneously, increased productive γ4 mRNA expression in IL-4- 
and sCD40L-stimulated PBMC. Consistently, quantification of the secreted 
immunoglobulins also verified our findings. Tr1 cells decreased IgE- and enhanced 
IgG4-secretion (Fig. 5B). Similar results are found considering the frequency of IgE- 
and IgG4-secreting plasma cells. Tr1 cells decreased the number of IgE-secreting 
plasma cells, but enhanced the number of IgG4-secreting plasma cells (Fig. 5C). For 
comparison, Der p 1 or bee venom phospholipase A2-specific IL-4-secreting and 
IFN-γ-secreting T cells were used in the same type of experiments. IL-4-secreting T 
cells significantly increased IgG4 and IgE production, whereas IFN-γ-secreting T 
cells did not affect IgE and IgG4 production (Fig. S2 in the Supplementary material). 
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Figure 5. Allergen-specific, IL-10-secreting Tr1 cells suppress IgE, but induce 
IgG4. Der p 1-specific, IL-10-secreting Tr1 cells are isolated from PBMC from 
healthy donors and incubated together with PBMC. (A) Quantitative RT-PCR 
determined at day 5 (n=3). (B) Supernatants analyzed for IgE and IgG4 at day 12 
(n=4). Conditions in the same experiment are linked with a line. (C) The frequency of 
IgE- and IgG4-secreting plasma cells measured at day 12 (1 representative of 3 
independent experiments is shown). * p < 0.05. 
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Differential effect of CD4+CD25+ Treg cells on IgE and IgG4 production by PBMC from 
healthy individuals 
We next investigated the influence of CD4+CD25+ Treg cells on immunoglobulin 
production. Similar to Tr1 cells, human peripheral blood CD4+CD25+ Treg cells also 
secrete IL-10 (222). Incubation of IL-4- and sCD40L-stimulated PBMC with 
CD4+CD25+ Treg cells from healthy individuals inhibited germline ε transcript 
expression, but they tend to induce productive γ4 transcript expression compared to 
CD4+CD25- T cells (Fig. 6A). The same effects of CD4+CD25+ Treg cells were 
observed on the protein level. As shown in Fig. 6B, CD4+CD25+ Treg cells 
suppressed IgE secretion, whereas IgG4 production was enhanced by IL-4- and 
sCD40L-stimulated PBMC. Freshly purified CD4+CD25+ T cells did not induce IgE or 
IgG4 production in conditions where IL-4 and sCD40L were not used, suggesting 
that Th2 help is required for the production of these Ig isotypes (Fig. S1 in the 
Supplementary material). Not surprisingly, also the frequency of IgE- and IgG4-
secreting plasma cells was decreased or enhanced, respectively, when CD4+CD25+ 
Treg cells were added to the IL-4- and sCD40L-stimulated PBMC cultures (Fig. 6C). 
CD4+CD25- T cells did not influence IL-4 and sCD40L-stimulated IgE or IgG4 
production. 
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Figure 6. Suppression of IgE and induction of IgG4 by CD4+CD25+ Treg cells. 
CD4+CD25+ and CD4+CD25- T cells are isolated from PBMC from healthy donors 
and cultured together with PBMC. (A) Quantitative mRNA for RT-PCR measured at 
day 5 (n=3). (B) IgE and IgG4 concentrations in the supernatants at day 12 (n=4). 
(C) The number of IgE- and IgG4-secreting B cells analysed at day 12 (1 
representative of 3 independent experiments is shown). * p < 0.05. 
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IL-10 counter regulates IgE and IgG4 
On the basis of the results above and since IL-10 is one of the major cytokines of 
both Tr1 cells and CD4+CD25+ Treg cells, we next wanted to investigate the role of 
this cytokine on the Ig regulation. IL-10 decreased IL-4 and sCD40L-induced 
germline ε transcript expression (Fig. 7A). In contrast, IL-4 and sCD40L-induced 
productive γ4 transcript expression is increased by IL-10. These effects of IL-10 
could be observed in a dose-dependent manner in the range of 2 to 50 ng/ml. The 
findings in quantitative PCR are confirmed by determination of Igs in the 
supernatants of 12 day-cultures. PBMC stimulated with IL-4 and sCD40L showed 
decreased IgE secretion in the presence of IL-10 (Fig. 7B). In the same cultures, IL-
10 synergized IL-4 and sCD40L-induced IgG4 secretion, whereas alone, it did 
induce only very small amounts of IgG4 (Fig. S1 in the Supplementary material). 
Similarly, IL-10 reduced the frequency of IgE-secreting plasma cells, whereas the 
IgG4-secreting plasma cell-frequency is enhanced (Fig. 7C). In unstimulated 
conditions, the frequency of IgE-producing plasma cells was practically negative. 
Only one spot per 50’000 cells was observed in 9 different experiments. The 
frequency of IgG4-producing plasma cells ranged between 0 to 4 spots per 50’000 
resting PBMC. In IL-4- and sCD40L-stimulated cultures IgE spots increased to 27-
59, IgG4 spots increased to 1-14 spots. Interestingly, the secreted protein of IgG4 
was relatively high compared to IgE, suggesting utilization of IgE in cultures, such as 
binding to CD23 (309). Blocking of the IL-10 receptor in CD4+CD25+ Treg co-cultures 
demonstrated that their suppression effect on IgE and their induction effect on IgG4 
are diminished (Fig. S3A in the Supplementary material). To strengthen the role of 
IL-10 as a soluble factor in the induction of IgG4, we performed transwell 
experiments, in which IL-10-secreting Tr1 cells were cultured in the upper well of the 
transwells and PBMC were cultured in the bottom of the transwells. IL-10-producing 
Tr1 cells induced IgG4 production without any requirement of cell-to-cell contact 
(Fig. S3B in the Supplementary material). In addition, IL-10 or IL-10Rα-chain were 
blocked by mAbs in the presence of IL-10. IgG4, which was significantly induced by 
IL-10 was almost 100% inhibited either by blocking the cytokine itself or its receptor 
(Fig. S3C in the Supplementary material). 
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Figure 7. IL-10 suppresses IgE and induces IgG4 production in PBMC. Human 
PBMC from healthy donors are cultured with different concentrations of IL-10. (A) 
Quantitative RT-PCR measured after 5 days of incubation (n=5). (B) Immunoglobulin 
concentrations in the supernatants determined at day 12 (n=4). (C) The frequency of 
IgE- and IgG4-secreting plasma cells measured at day 12 (1 representative of 3 
independent experiments is shown). (B), (C) IL-10 was used at 50 ng/ml. * p < 0.05.  
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Direct effect of Tr1 cells, CD4+CD25+ Treg cells and IL-10 on IgE and IgG4 production in pure 
B cells 
To eliminate indirect effects of other cells in PBMC, we investigated the impact of IL-
10-secreting Tr1 cells, CD4+CD25+ Treg cells and IL-10 on purified B cells. B cells 
were cultured in the presence of IL-4 and sCD40L. As observed in PBMC, addition 
of Der p 1-specific Tr1 cells, CD4+CD25+ Treg cells or IL-10 decreased germline ε 
transcript expression. Productive γ4 transcript expression was increased by Tr1 
cells, CD4+CD25+ Treg cells and IL-10 (Fig. 8A). Considering the Ig-protein level, 
IgE secretion was diminished in the presence of Tr1 cells, CD4+CD25+ Treg cells or 
IL-10, but IgG4 secretion was strongly enhanced (Fig. 8B).  
Therefore, we conclude, that antigen-specific, IL-10-secreting Tr1 cells and 
CD4+CD25+ Treg cells are able to reduce IgE production at the mRNA-, the protein- 
and the plasma cell frequency-level. Simultaneously, antigen-specific, IL-10-
secreting Tr1 cells and CD4+CD25+ Treg cells can efficiently induce IgG4 production. 
The data is confirmed in 50 different experiments demonstrated in Fig. 5-8. 
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Figure 8. IL-10-secreting Tr1 cells and CD4+CD25+ Treg cells regulate B cells. B 
cells, IL-10-secreting Tr1 cells, CD4+CD25+ and CD4+CD25- T cells are isolated from 
PBMC from healthy individuals. (A) Quantitative RT-PCR determined after 5 days of 
incubation of B cells with IL-10 (50 ng/ml), Tr1 cells, CD4+CD25+ and CD4+CD25- T 
cells (mean values ± SE; n=9). (B) Immunoglobulin concentrations measured at day 
12 in the supernatants (mean values ± SE; n=9). * p < 0.05. 
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IgA is induced by TLR7 or 9 stimulation but not by T cell help 
Because neither Tr1 cells nor CD4+CD25+ Treg cells nor CD4+CD25- T cells nor IL-
10 showed any influence on IgA production in PBMC as well as in pure B cell 
cultures (Fig. S4A in the Supplementary material), we then investigated an array of 
TLR agonists for their capacity to induce IgA. PBMC were cultured in the presence 
of different TLR agonists. While stimulation of TLR2, 3, 4, 5, or 8 was not able to 
influence the IgA production (Fig. S4B in the Supplementary material), triggering of 
TLR7 or 9 highly enhanced both the mRNA level and the secretion of IgA compared 
to IgE and IgG4 (Fig. 9A and B).  Interestingly, the addition of IL-4 and sCD40L to 
the cultures suppressed TLR7 or 9 induced IgA production, but upregulated IgE and 
IgG4 (Fig. S4B in the Supplementary material). Although dose dependent 
optimization was performed in preliminary experiments, TLR9 stimulation by type B 
CpG has always been the most potent stimulus compared to TLR7 for the induction 
of IgA. As a control, we also used type A CpGs, which could not induce IgA (Fig. S5 
in the Supplementary material). We conclude that the IgA production is not 
influenced by Tr1 and CD4+CD25+ regulatory T cells, but rather induced by the 
innate immune system via activation of TLR7 or 9 stimulation. 
 
 
 
Figure 9. Induction of IgA requires TLR7 and 9 triggering. PBMC from healthy 
individuals are stimulated with TLR3, 7 or 9 ligands. (A) Quantitative RT-PCR 
determined after 5 days of incubation (n=3). (B) IgA, IgE and IgG4 concentrations in 
the supernatants measured after 12 days (n=4). 
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Discussion 
In the present study, we demonstrate that the function of T regulatory cells is not 
only to suppress Th1 or Th2 cell responses, but that those cells also have direct 
influence on B cells. Tr1 cells and CD4+CD25+ Treg cells suppressed IgE and 
induced IgG4. Both regulatory T cell subsets also lowered IgE-secreting, and 
simultaneously augmented the IgG4-secreting plasma cell-frequency. In lymph 
nodes and tonsils, Foxp3+ Treg cells are present in B cell areas where T-B cell 
interaction and humoral immune responses occur, and can directly suppress B cell 
Ig production and class switch recombination without a prerequisite to suppress Th 
cells. This is supported by studies, which show decreased Treg cell function or 
number in several immune mediated diseases in humans and mouse models with 
increased autoantibody production (310,311).  
Studies on the mechanisms of immune responses to allergens have 
demonstrated that Treg cells are dominant in healthy individuals (87,312). If a 
detectable immune response is mounted, Tr1 cells specific for common 
environmental allergens, consistently represent the dominant subset. Healthy and 
allergic individuals exhibit the Th1, Th2 and Tr1 type, allergen-specific subsets in 
different proportions (87). Accordingly, a change in the dominant subset and the 
balance between Th2 and Treg cells may lead to either allergy development or 
recovery. CD4+CD25+ Treg cells have been associated with the spontaneous 
remission of Cow’s milk allergy. Children who outgrew their allergy (tolerant children) 
had higher frequencies of circulating CD4+CD25+ T cells and decreased in vitro 
proliferative responses to bovine beta-lactoglobulin in PBMC compared with children 
who maintained clinically active allergy (313). Several studies have suggested that 
children with a cat at home have a decreased risk of sensitization and asthma. 
Children exposed to more than 20 µg of Fel d 1 per 1 g of house dust display an 
IgG4 antibody response to Fel d 1 without IgE antibody. This modified Th2 response 
is not associated with symptoms and has been regarded as a form of immunological 
tolerance (314). 
Although peripheral T cell tolerance is rapidly induced during specific 
immunotherapy (SIT), there is no evidence for B cell tolerance in the early course 
(315). Especially IgG4, which increases during the course of SIT or natural high 
dose exposure, is thought to capture the allergen before reaching the effector cell-
bound IgE, and thus to prevent the activation of mast cells and basophils (316). 
Allergen-specific IgG4 may be directed against the same epitopes as IgE, resulting 
in direct competition for allergen binding and a “blocking” effect (215). It has been 
proposed that successful specific immunotherapy is associated with an increase in 
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IgG blocking activity that is not solely dependent on the quantity of IgG antibodies 
(215,218). 
The non-inflammatory role for IgG4 may be because the IgG4 hinge region 
has unique structural features that result in a lower affinity for certain Fcγ receptors 
and the ability to separate and pair again, leading to bi-specific antibodies that are 
functionally monomeric (44,45). Furthermore, IgG4 does not fix complement and is 
unable to form large immune complexes. In an allergen-specific immunotherapy 
study, in which well-defined recombinant allergen mixtures were used, all treated 
persons developed very strong allergen-specific IgG4 and also increased IgG1 
antibody responses. Some patients, who were not initially sensitized to Phleum 
pratense group 5 (Phl p 5), developed strong specific IgG4, but not IgE antibody 
responses to that allergen (317). 
IL-10 is a potent suppressor of both total and allergen-specific IgE, while it 
simultaneously increases IgG4 production (98,129). Thus, IL-10 not only generates 
tolerance in T cells; it also regulates specific isotype formation and skews the 
specific response from an IgE to an IgG4 dominated phenotype. The healthy 
immune response to Der p 1 demonstrated increased specific IgA and IgG4, small 
amounts of IgG1 and almost undetectable IgE antibodies in serum (222). House dust 
mite-SIT did not significantly change specific IgE levels after 70 days of treatment; 
however, a significant increase in specific IgA, IgG1 and IgG4 was observed (222). 
Most probably the decrease in IgE/IgG4 ratio during allergen-SIT is a feature of 
skewing an allergen-specific Th2 to a Treg cell predominance. However, although 
Treg cell generation happens within days, a significant decrease in IgE/IgG4 ratio 
occurs after several months. The reason for the long-time gap between the change 
in T cell subsets, but not IgE/IgG4 levels is not easily explainable by the half-life of 
antibodies. In this context, the role of bone marrow-residing IgE-producing plasma 
cells with very long lifespan remains to be investigated (318). To increase the 
efficacy of allergen-SIT a search for good adjuvants is efficiently being pursued. 
Usage of TLR7/9 triggering substances together with recombinant proteins may 
have a beneficial effect in allergen-specific immunotherapy. In this way, the blocking 
antibody isotype IgA is expected to increase simultaneously and support or even 
synergize the advantageous effects of IgG4 (218,319). 
In this study, we demonstrate that IgA production is neither influenced by IL-
10 nor by IL-10 secreting Tr1 cells nor by CD4+CD25+ Treg cells. This antibody 
isotype is particularly regulated by activation of the innate immune system. Addition 
of TLR7 or 9 agonists to PBMC cultures highly upregulated IgA production and 
secretion, whereas T cell-help to B cells seems not to be necessary, since Tr1 cells, 
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CD4+CD25+ Treg cells as well as IL-4 and sCD40L did not have any effect on IgA. 
Recent evidence indicates that TLR stimulation on B cells can control 
immunoglobulin isotype switch. TLR and MyD88 are required for class switching to 
the pathogenetic IgG2a and IgG2b isotypes, but not for the development of IgM 
autoantibodies (186). Furthermore, CpG, but not LPS, upregulates T-bet expression 
in B cells and induces IgG2a, whereas it decreases IgG1 and IgE production 
(187,188). In human B cells, TLR9 stimulation by CpG-DNA, in association with IL-
10, initiates germline immunoglobulin heavy chain constant region Cγ1, Cγ2 and Cγ3 
gene transcription (190). Besides having a direct effect on B cells, TLR agonists can 
affect B cell differentiation and isotype switch indirectly through activation of DCs 
and subsequent release of IFN-α and IL-6. Recently, it has been shown that gut DCs 
induce IgA class switch by synergistic effects of retinoic acid, IL-6 and IL-5 (195), 
however, the role of TLRs in DC-mediated IgA induction remains to be elucidated. In 
another study, IFN-α-, IFN-γ-, LPS- or CD40L-stimulated human dendritic cells up-
regulated BAFF and APRIL, which induced together with IL-4, IL-10 or TGF-β CD40-
independent class-switch recombination to Cγ, Cα or Cε in B cells (192). In addition, 
TLR ligands and APRIL were shown to synergize to further enhance IgA2 class 
switching (320). Moreover, it has been demonstrated that inducible-nitric-oxide-
synthase (iNOS) induces TGF-βRII on B cells and controls T-cell-dependent IgA 
class-switch recombination. Furthermore, MALT DCs express iNOS in response to 
the recognition of commensal bacteria by TLRs, which in turn leads to the production 
of BAFF and APRIL and subsequent T-cell-independent IgA class-switch 
recombination in B1 cells (321).  
If the mechanism by which regulatory T cells act on B cells consists of 
physical cell-to-cell contact via intercellular adhesion molecule 1 (ICAM-1), TGF-β 
(130), cytotoxic T cell-associated antigen-4 (CTLA-4) (322), glucocorticoid-induced 
tumor necrosis factor receptor (GITR) (323), programmed death-1 (PD-1) (324) and 
OX40 (CD134) (325), or, as very recently shown, via cyclic adenosine 
monophosphate and gap junctions (326), or if it is more an autocrine mechanism 
with IL-10 and TGF-β as soluble mediators, is not known yet. It appears however, 
that this antibody isotype regulation is partially dependent on IL-10 as demonstrated 
in our inhibition experiments with anti-IL-10 and anti-IL-10 receptor-antibodies and 
the transwell experiment (Fig. S3 in the Supplementary material). 
We conclude that peripheral tolerance utilizes multiple mechanisms to 
suppress allergic inflammation. Apparently, Treg cells contribute to the control of 
allergen-specific immune responses in several ways: Suppression of antigen-
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presenting cells that support the generation of effector Th2 and Th1 cells; 
suppression of Th2 and Th1 cells; suppression of mast cells, basophils and 
eosinophils; interaction with resident tissue cells and remodeling (88). In addition to 
the above mechanisms, the present study demonstrates suppression of IgE and 
induction of the non-inflammatory antibody isotype IgG4 by Tr1 and CD4+CD25+ 
Treg cells.  
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Supplementary material 
Methods 
Determination of IgE, IgG4 and IgA 
Quantitative real-time PCR: After 5 days in cell culture, cells were lysed with RNeasy 
lysis buffer, and the RNA was isolated using the RNeasy mini kit (QIAGEN, Hilden, 
Germany) and eluted in 50 µl ddH2O. Reverse transcription was performed with 
RevertAid M-MuLV Reverse Transcriptase, Random Hexamer Primers, dNTP Mix, 
Ribo Lock RNase Inhibitor (all from Fermentas Burlington, Canada). The primers 
detecting germline transcripts of IgE (Iε-Cε), productive transcripts of IgG4 (JH-Cγ4) 
and productive transcripts of IgA (Cα-Cα) were designed from appropriate database 
sequences using the PrimerExpress software (Applied Biosystems). Primers (all 
Microsynth, Balgach, Switzerland) used were as follows: IgE forward primer, 5'-ACA 
CAT CCA CAG GCA CCA AA-3', IgE reverse primer, 5'-TTG CAG CAG CGG GTC 
AA-3'; IgG4 forward primer, 5'-ACC C/ATG GTC ACC GTC TCC TCA-3', IgG4 
reverse primer, 5'-GGG ACC ATA TTT GGA CTC-3'; IgA forward primer, 5'-CGC 
TGG CCT TCA CAC AGA A-3', IgA reverse primer, 5'-CGC CAT GAC AAC AGA 
CAC A-3'. cDNAs were amplified using SYBR®-PCR mastermix (Applied 
Biosystems, Branchburg, NJ, USA) according to the recommendations of the 
manufacturer in a total volume of 25 µl in a sequence detection system (ABI PRISM 
7000; Applied Biosystems). Relative quantification was performed as described 
previously (87). The obtained values were normalized to the amount of 18S rRNA 
present in each sample. All amplifications were performed in triplicates. 
ELISA: Secreted immunoglobulins were detected by ELISA on day 12. ELISA 
plates (Nunc, Roskilde, Denmark) were coated with 20 µg/ml purified mouse anti-
human IgE (Novartis, Basel, Switzerland), 1 µg/ml purified mouse anti-human IgG4 
or 1 µg/ml purified mouse anti-human IgA (both from BD Pharmingen, San Diego, 
CA, USA) Abs. IgE and IgG4 plates were blocked with PBS containing 1% BSA 
(Fluka, Buchs, Switzerland), IgA plates with PBS containing 2.5% milk powder. 
Supernatants were added to the plates and incubated at room temperature. Plates 
were then washed with PBS containing 0.05% Tween 20 (Fluka, Buchs, Switzerland) 
and incubated with biotinylated isotype-specific secondary antibodies (for IgE-ELISA 
from Novartis, Basel, Switzerland; for IgG- and IgA-ELISA from BD Pharmingen, San 
Diego, CA, USA) followed by extravidin peroxidase conjugate (Sigma-Aldrich, 
Steinheim, Germany). The assay was developed with 2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS, Sigma-Aldrich, Steinheim, Germany) as 
chromogenic substrate. All measurements were performed in duplicates. 
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ELISPOT: The frequency of Ig-secreting cells was determined by ELISPOT 
on day 12. Filter plates (Pall Corporation, Ann Arbor, USA) were coated with 20 
µg/ml purified mouse anti-human IgE (Novartis, Basel, Switzerland) or 4 µg/ml 
purified mouse anti-human IgG4, RJ4 (Beckman Coulter, Fullerton, CA, USA) Abs. 
The plates were blocked with PBS containing 1% BSA (Fluka, Buchs, Switzerland). 
50’000 cells/well were added to the plates and incubated overnight at 37°C. Plates 
were then washed with PBS containing 0.05% Tween 20 (Fluka, Buchs, Switzerland) 
and incubated with a biotinylated IgE-specific secondary antibody (Novartis, Basel, 
Switzerland) followed by ExtrAvidin-Alkaline phosphatase (AP) conjugate (Sigma-
Aldrich, Steinheim, Germany) or they were incubated with an anti-human IgG-AP 
conjugate. The assay was developed with 5-Brom-4-Chlor-3-
Indolylphosphat/Nitroblau Tetrazolium (BCIP/NBT) (BIO-RAD, Reinach, Switzerland) 
as chromogenic substrate. All measurements were performed in triplicates. 
 
CpG oligonucleotides, antibodies 
Type B CpG2006 and the two type A CpGs, CpG2216 and CpG10, were all from 
Microsynth GmbH, Balgach, Switzerland. For sequences see reference (327). Anti-
IL-10 mAb was purchased from R&D systems. 
 
Transwell membrane system 
We used transwell permeable supports from Corning Incorporated, NY, USA (3.0 µm 
polycarbonate membrane, 6.5 mm insert, 24 well plate). 6’600 IL-10-secreting Tr1 
cells were cultured in the upper compartment of the transwells and 1.5x106 PBMC 
were cultured in the lower compartment. Quantitative RT-PCR was performed after 5 
days of incubation. 
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Figure S1. IgG4 and IgE are not strongly induced by IL-10, IL-10-secreting Tr1 
cells or CD4+CD25+ Treg cells without IL-4 and sCD40L. PBMC from healthy 
individuals were incubated with IL-10 (50 ng/ml), IL-10-secreting Tr1 cells or 
CD4+CD25+ Treg cells. (A) Quantitative RT-PCR determined after 5 days of 
incubation (mean values ± SE; n=4). (B) The IgE and IgG4 concentrations in the 
supernatants measured after 12 days of incubation (mean values ± SE; n=4). 
Results
 
 70 
 
 
Figure S2. Regulation of IgE and IgG4 by IL-4- and IFN-γ -secreting cells. Der p 1 
or bee venom phospholipase A2-specific IL-4-secreting and IFN-γ-secreting T cells 
were used as controls. IL-4-secreting T cells significantly increased IgG4 and IgE 
production, whereas IFN-γ-secreting T cells did not affect IgE and IgG4 production.
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Figure S3. Role of IL-10 in suppression of IgE and induction of IgG4 by Treg 
cells. B cells from healthy individuals are incubated with CD4+CD25+ Treg cells or 
with CD4+CD25- T cells. Quantitative RT-PCR determined after 5 days of incubation. 
(A) IgE germline transcripts and IgG4 productive transcripts (one representative 
experiment). (B) IL-10-secreting Tr1 cells were cultured in the upper compartment of 
the transwells and PBMC were cultured in the lower compartment. IL-10-producing 
Tr1 cells induced IgG4 production without any requirement of cell-to-cell contact 
(data represent 2 independent experiments). (C) In PBMC, IL-10 or IL-10Rα-chain 
was blocked by mAbs in the presence of IL-10. IgG4, which was significantly 
induced by IL-10 was strongly inhibited either by blocking the cytokine itself or its 
receptor (data represent 3 independent experiments) * p < 0.05. IC: isotype control.
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Figure S4. IgA is elicited by stimulation of TLR7 or 9 but not by IL-10, IL-10-
secreting Tr1 cells or CD4+CD25+ Treg cells. (A) PBMC or pure B cells from 
healthy individuals are incubated with IL-10 (50 ng/ml), IL-10-secreting Tr1 cells or 
CD4+CD25+ Treg cells. Quantitative RT-PCR determined after 5 days of incubation 
(mean values ± SE; n=3-5). (B) PBMC from healthy individuals are stimulated with 
TLR2, 3, 4, 5, 7, 8 or 9 ligands. Quantitative RT-PCR determined after 5 days of 
incubation (n=3). IL-4 and sCD40L, which upregulated IgE and IgG4 suppressed 
TLR7 and TLR9 induced IgA.  
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Figure S5. IgA was determined after stimulation of PBMC with type B CpG2006 and 
type A CpG10 and CpG2216 (data represent 3 independent experiments). CpG2006 
was found to be the most potent inducer of IgA. In contrast, induction of IgA by A 
type CpGs was very weak. IgA mRNA was detected on day 5. 
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Abstract 
High dose bee venom exposure in beekeepers by natural bee stings represents a 
model to understand mechanisms of T cell tolerance to allergens in healthy 
individuals. Continuous exposure of non-allergic beekeepers to high doses of bee 
venom antigens induces diminished T cell-related cutaneous late-phase swelling to 
bee stings in parallel with suppressed allergen-specific T cell proliferation and Th1 
and Th2 cytokine secretion. After multiple bee stings, venom antigen-specific Th1 
and Th2 cells show a clonal switch towards interleukin (IL)-10-secreting type 1 T 
regulatory (Tr1) cells. T cell regulation continues as long as antigen exposure 
persists and returns to initial levels within two to three months after bee stings. 
Histamine receptor 2 upregulated on specific Th2 cells displays a dual effect by 
directly suppressing allergen-stimulated T cells and increasing IL-10 production. In 
addition, cytotoxic T lymphocyte-associated antigen-4 and programmed death-1 play 
roles in allergen-specific T cell suppression. In contrast to its role in mucosal allergen 
tolerance, TGF-β does not seem to be an essential player in skin related allergen 
tolerance. Thus, rapid clonal switch to IL-10-producing Tr1 cells and the use of 
multiple suppressive factors represent essential mechanisms in immune tolerance to 
high dose of allergens. 
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Introduction 
To avoid chronic cell activation and inflammation against nonpathogenic antigens 
through skin, ingestion and inhalation, the immune system has developed efficient 
peripheral tolerance mechanisms. Allergic diseases are due to an aberrant immune 
response mediated through a key effector cell, the T helper (Th) type 2 cell and 
associated cytokine pattern including IL-4, IL-5 and IL-13 (328). Consequently, the 
most pronounced findings with potential relevance to allergy therapy are related 
directly to the control of these Th2 immune effectors. There is strong evidence that 
peripheral T cell regulation plays a crucial role in the control of harmful T cell 
responses. Since the early 1970s many types of suppressor mechanisms have been 
demonstrated, and the biology of T regulatory (Treg) cells has been the subject of 
intensive investigation (329-333).  
Subsets of Treg cells with distinct phenotypes and mechanisms of action include the 
naturally occurring, thymic selected CD4+CD25+FoxP3+ Treg cells, and the inducible 
type 1 Treg cells (Tr1) (98,100,121,334-336). A great deal of uncertainty remains 
about differentiation factors, antigen specificity and mechanisms of action of Treg 
cells. Several types of adaptive Treg cells have been described with a unique 
mechanism of action that varies depending on the experimental model. Treg cells act 
as suppressor T cells, which down regulate effector cells and antigen-presenting 
cells in vitro and in inflammation models such as various chronic infections, organ 
transplantation, allergy and autoimmunity (98,100,121,334-336). Although molecular 
mechanisms of Treg cell generation remain to be elucidated, some existing therapies 
for allergic diseases such as treatment with glucocorticoids, and beta-2 agonists 
might function, to promote the numbers and function of IL-10-secreting Tr1-like cells 
(99,337). 
Studies on the immune response to allergens provide well-defined models for 
understanding the regulation and circumvention of antigen-specific T-cell responses. 
The symptoms of immunoglobulin-E-mediated allergy–rhinitis, conjunctivitis and 
asthma can be ameliorated by the temporary suppression of mediators and immune 
cells (such as anti-histamines and corticosteroids) (92,338). However, the only long-
term solution for the treatment of allergy is allergen-specific immunotherapy by the 
administration of high doses of allergen or allergen peptides that specifically target T 
cells over a long period of time (338). Successful venom and aeroallergen 
immunotherapy is associated with the induction of peripheral tolerance in T cells by 
generation of Treg cells that secrete suppressive cytokines, IL-10 and TGF-β, 
suggesting that generation of Tr1 cells may play a role in healthy immune responses 
(87,312).  
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Investigation of allergen-specific peripheral T cell response in non-allergic 
beekeepers in and out of the bee keeping season has enabled us to study essential 
questions in peripheral T cell tolerance. One bee sting contains approximately 50 µg 
of protein consisting of several different antigens, which are directly inoculated into 
the skin. The major allergen phospholipase A2 (PLA) is responsible for allergic 
reactions in almost all of the sensitized individuals and comprises approximately 10 
to 20 % of bee venom’s protein content (339). In the present study, we used several 
direct methods to analyse human specific T cell response in beekeepers, who were 
followed for consecutive years in and out of the bee keeping season. This represents 
a relevant model to investigate mechanisms of immune tolerance to high dose of 
allergen exposure in humans. 
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Results 
High Dose Allergen Exposure Via Skin Induces Decreased Cutaneous Late-Phase 
Responses and Unresponsiveness in Allergen-Specific T Cells.  
Beekeepers investigated in this study are not allergic to bee venom, but show 
significant cutaneous late-phase responses and peripheral blood T cell proliferation 
and cytokine production in response to bee venom major allergen, PLA. They do not 
use protective masks or gloves and receive numerous bee stings during their 
occupation. They start beekeeping in the last week of April and continue until 
October (Fig. 10A). Their exposure to high doses of venom antigens induces 
decreased cutaneous late-phase swelling response to bee stings within a few days, 
which continues throughout the whole season as long as antigen exposure persists. 
The size of skin reactions to bee stings return to initial levels a few months after the 
end of each season. In the beginning of the next beekeeping season, they 
experience the same degree of skin reactivity, again only in the first few bee stings 
(Fig. 10B). T cells play a major role in cutaneous late-phase responses and lesion 
size correlates with infiltrating T cell numbers (340). By monitoring peripheral blood T 
cell response in beekeepers for several years, a significant decrease in peripheral 
blood mononuclear cell (PBMC) proliferation against PLA, after multiple bee stings 
has been demonstrated (Fig. 10C). Approximately two months after the end of the 
beekeeping season, PLA-specific T cell proliferation returned to initial high levels. 
Beekeepers, who are followed two to three consecutive years showed the same T 
cell response profile every year, demonstrating a short lived peripheral T cell 
unresponsiveness, which depends on antigen exposure and its persistence. PBMC 
proliferative response to control antigens, PPD and tetanus toxoid did not show any 
change during bee stings (Fig. 10D).  
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Figure 10. Decreased antigen-specific T cell response and cutaneous late-
phase response after natural high dose antigen exposure. a) The number of 
beestings per month is demonstrated in 9 beekeepers b) Decreased cutaneous late-
phase response after bee stings returns to initial levels upon no exposure (5 
beekeepers followed for three years. Lesion size has been graded as 2: >3 cm, 1: 0-
3 cm, 0:no swelling) and cutaneous late-phase response lesion size in 9 beekeepers 
(inner panel) in 2007 before and 7 days after bee stings c) PLA-induced [3H] 
thymidine incorporation in PBMC after 5 days in two beekeepers followed for three 
and two beekeepers for two consecutive years (67 peripheral blood samples). PLA-
induced [3H] thymidine incorporations analysed in 29 experiments before and 7 d 
after bee stings between 2001 and 2007 (inner panel). d) T cell proliferation against 
control antigens (PPD and tetanus toxoid) did not show any change in 3 beekeepers 
throughout the year. (*:p<0.001).  
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Increased IL-10-Secreting Tr1-Like T cell Response Immediately After High Dose 
Venom Exposure.  
To investigate the mechanism of T cell unresponsiveness, PLA-specific T cells were 
characterized before and after multiple bee stings. First, their frequency was 
determined according to their IL-4-, IFN-γ− and IL-10-secretion profile before and 7 
days after bee stings. Although the overall frequency of PLA-specific T cells showed 
a slight increase from 12.4 to 14.8 in 10’000 CD4+ T cells, a remarkable shift to IL-
10-secretion in specific T cells was observed (Fig. 11A, B). In 10'000 CD4+ T cells, 
the frequency of PLA-specific IL-4-secreting cells decreased from 1.23 ± 0.32 to 0.43 
± 0.17; IFN-γ-secreting T cells decreased from 5.66 ± 0.92 to 2.49 ± 0.76. In 
contrast, the frequency of PLA-specific IL-10-secreting T cells increased from 5.52 ± 
1.93 to 11.87 ± 3.12. The shift in the frequency of cytokine-secreting T cells was 
strongly supported by changes in overall cytokine profile of PLA-specific T cells after 
multiple bee stings (Fig. 11C, D). Before bee stings and other times out of the bee 
keeping season (December to February), PLA-specific T cells showed an IL-10- and 
IFN-γ-predominant cytokine profile with relatively less IL-4 and IL-13 secretion. 
Again, 7 days after they received multiple bee stings, IL-10-production in PLA-
stimulated T cells increased, whereas IFN-γ-, IL-4- and IL-13-production decreased.  
As shown above, all three subsets of single allergen-specific T cells are 
present in healthy beekeepers and skew to IL-10-secreting T cells in vivo. 
Accordingly, their role on PLA-induced T cell proliferation and whether this is 
influenced by changing their ratios was investigated. We assayed the allergen-
induced proliferation of IFN-γ-, IL-4- and IL-10-secreting T cells by adding those 
purified cells back into autologous PBMC. Their frequency was increased up to 10 
times higher than initial levels in PBMC (Fig. 11E). PLA-, Bet v 1- and Der p 1-
specific IL-10-secreting T cells were purified from the same beekeeper. PLA-induced 
T cell proliferation, which was abolished after bee stings was reconstituted by 
increasing the numbers of PLA-specific IFN-γ- and IL-4-, but not IL-10-secreting T 
cells. PLA-specific IL-10-secreting T cells suppressed PLA-stimulated proliferating T 
cells, which secrete IL-4 and IFN-γ. For comparison, Bet v 1- and Der p 1-specific IL-
10-secreting T cells did not suppress PLA-stimulated T cell proliferation, 
demonstrating the allergen specificity of bee venom induced T cell 
unresponsiveness. 
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Figure 11. Increased allergen-specific Tr1 and decreased Th1 and Th2 cells 
after bee stings. a) PLA-specific IL-4-, IL-10- and IFN-γ-secreting CD4+ T cells are 
purified and their frequency calculated in 6 beekeepers before the beginning of bee 
keeping season and after 7 d. They received an average of 13 bee stings. b) 
Frequency of PLA-stimulated cytokine-secreting cells in 6 beekeepers measured by 
ELISPOT assay. c) Secreted cytokines are measured in PLA-stimulated PBMC 
cultures (IL-4 after 24 h, IL-13, IFN-γ and IL-10 day 5) by ELISA. d) PBMC from 
beekeepers are stimulated with PLA for 7 d and intracytoplasmic cytokines were 
determined 12 h after anti-CD2/CD3/CD28 mAb stimulation. Mean percent 
difference (standard deviations are in brackets) of 8 experiments is shown before 
and 7 days after multiple bee stings inside each histogram. e) PLA- specific IL-4-, IL-
10- and IFN-γ-secreting and Der p 1- and Bet v 1-specific IL-10-secreting T cells 
were purified from beekeepers after multiple bee stings. Their frequency was 
calculated in CD4+ T cells and 2x105 PBMC were immediately reconstituted by 
increasing their frequency in cultures by 10 times (IL-4-secreting T cells 0.02 % to 
0.2 %; IL-10-secreting T cells 0.1 % to 1 %, IFN-γ-secreting T cells 0.05% to 0.5%). 
Cells were stimulated with PLA and [3H]thymidine incorporation was determined after 
5 d (similar results were obtained in three experiments). *:p< 0.001. 
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In Vivo Clonal Switch of Allergen-Specific Th2 and Th1 Cells Towards IL-10-
Secreting Tr1 Cells.  
After the observation of a change in T cell cytokine profile within 7 days in vivo, we 
investigated whether the increase in allergen-specific Tr1 cells occurs as a switch in 
cytokine profile and clonal expansion from specific memory Th1 and Th2 cells or 
new Tr1 cells are generated from the naïve T cell pool (Fig. 12). By using primers 
spanning different parts of T cell receptor (TcR) variable β chain, we demonstrated 
that purified PLA-specific IFN-γ-, IL-4- and IL-10-secreting T cells consisted of clonal 
T cells in vivo. After bee stings, their clonality increased particularly in IL-10-
secreting T cells and decreased or disappeared in IFN-γ-secreting T cells. Very 
interestingly, the clonality of IFN-γ-secreting T cells disappeared and clonality in IL-
10-secreting T cells appeared in a certain TcRvβ group of T cells detected by primer 
set D.  
To further support the data on in vivo clonal switch to Tr1 cells, again PLA-
specific IL-4-, IL-10- and IFN-γ-secreting T cells were purified and expanded with IL-
2. CD4+ T cells were stained with a panel of T cell receptor vβ chain mAbs and their 
frequency was determined (Fig. 13). 7 days after multiple bee stings, a switch in TcR 
vβ2 positive T cells from IL-4-secretion to IL-10-secretion profile was observed. In 
addition, TcR vβ12-bearing T cells skewed from an IFN-γ- and IL-4-dominant profile 
towards an IL-10-dominant profile. In another beekeeper, an increase in TcR vβ8-
positive IL-10-secreting T cells and decreased TcR vβ17-positive IL-4- and IFN-γ-
secreting T cells was demonstrated after bee stings. It has to be noted that the 
allergen-specific T cell population analysed here represent 0.1 to 0.01 % of all T 
cells. Together, these data demonstrate that an in vivo clonal switch occurs in 
allergen-specific CD4+ T cells towards IL-10-secreting T cells after multiple bee 
stings. 
 
 
 
 
 
 
Results
 
 84 
 
 
Figure 12. Clonal skew to IL-10-secreting T cells after bee stings. T cell receptor 
beta gene clonality is analysed in PLA-specific IL-4-, IL-10- and IFN-γ-secreting T 
cells before and 7 d after multiple bee stings. A clonal sample (C) and a non-clonal 
sample (N) are included as controls. The PCR products of three different test tubes 
are run on three different gels and a band which results from a clonal sample 
appears in a range from 240 bp – 285 bp (primers A, tube 1), 240 bp – 285 bp 
(primers B, tube 2), 170 bp – 210 bp and 285 bp – 325 bp (primers C and D, tube 3). 
The specimen control size ladder master mix generates a series of amplicons to 
ensure that the quality and quantity of input DNA is sufficient for the test. 
Heteroduplex analysis of the PCR products (except for the Specimen Control Size 
Ladder) on 6% TBE polyacrylamid gels, stained with ethidium bromide is shown. 
One representative from three experiments is shown. 
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Figure 13. In vivo switch from PLA-specific IL-4- and IFN-γ-secreting towards 
IL-10-secreting CD4+ T cells in TcRVβ2-, 8- and 12- expressing T cells. Two 
beekeepers were analyzed for TcRVβ chain expression in purified PLA-specific IL-4-
, IL-10- and IFN-γ-secreting T cells by gating CD4+ T cells by flow cytometry. The 
whole panel of TcR mAbs have been used for staining. Significant switch in certain 
TcR positive cell percentage between T cell subsets after bee stings is shown. 
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Role of Histamine Receptor 2 in Peripheral T Cell Tolerance.  
Piecemeal degranulation of mast cells and basophils below the threshold of systemic 
anaphylaxis occurs by bee stings and histamine is released as one of the main 
mediators (339). Accordingly, we investigated the regulation of histamine receptors 
(HR) on allergen-specific T cells. HR2 showed a significant increase in allergen-
stimulated T cells 7 d after multiple beestings (Fig. 14A). There was no change in 
HR1, HR4 and FoxP3 expression and PHA- and PPD-stimulated T cells. We further 
investigated the in vivo expression levels of HR2 mRNA in allergen-specific IL-4-, 
IFN-γ− and IL-10-secreting T cells immediately after purification (Fig. 14B). After bee 
stings, HR2 was exclusively upregulated on Th2-like IL-4-secreting T cells without 
showing any difference in IFN-γ- and IL-10-secreting T cells. The expression of 
FoxP3 was relatively low in allergen-stimulated cells compared to CD4+CD25+ cells 
purified from beekeepers and did not show any change after bee stings in both 
allergen-stimulated cultures and whole CD4+CD25+ population. There was also no 
change in CD4+CD25+ T cell percentages after bee stings (data not shown). 
Whether increased HR2 on Th2 cells has a role in IL-10 secretion in T cells was next 
investigated. PLA-specific IL-4-secreting T cells were stimulated with different doses 
of histamine in the presence or absence of HR2 antagonist ranitidine. Histamine 
dose dependently decreased IL-4 and IL-13 production and upregulated IL-10 
production in T cells. This effect was specifically due to HR2 triggering, because of 
complete suppression by ranitidine (Fig. 14C). 
The role of HR2 and IL-10 in allergen-specific T cell suppression was 
investigated by using an IL-10 receptor blocking mAb and ranitidine in PLA-
stimulated T cells before and after bee stings. Before bee stings 3.22 ± 0.71 of 
CD3+CD4+ T cell showed divisions by PLA stimulation. IL-10 significantly 
suppressed this proliferation to background levels. 7 d after bee stings, PLA-specific 
proliferating CD3+CD4+ T cells significantly decreased to 0.86 ± 0.41. It was 
observed that most of the suppression induced 7 days after multiple bee stings has 
been recovered by blocking of IL-10 receptor and histamine receptor 2 and there 
was an additive effect of both as demonstrated in [3H]-thymidine incorporation (Fig. 
15A, B). 
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Figure 14. HR2 is upregulated in specific T cells after multiple beestings and 
induces IL-10 production. a) PBMC are stimulated with PLA for 7 days. HR1, HR2, 
HR4 and FoxP3 mRNAs were determined 4 hours after anti-CD3/ anti-CD28 mAb 
stimulation before and 7 d after multiple bee stings. For comparison PPD- and PHA-
stimulated cells did not show any difference. b) HR2 and FoxP3 have been analysed 
in purified allergen specific IL-4-, IL-10- and IFN-γ-secreting T cells immediately after 
purification and CD4+CD25+ and CD4+CD25- T cells. c) PLA-specific IL-4-secreting T 
cells were purified and stimulated with different doses of histamine in the presence 
or absence of 10-4 M ranitidine. Cytokines were determined by ELISA after 3 days. 
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Figure 15. HR2 and IL-10 play major roles in peripheral T cell tolerance to high 
dose antigen exposure. a) PBMC of beekeepers were labeled with CFSE and 
dilutions in CFSE-expressing cells were analysed in the presence of IL-10, anti-IL10 
receptor mAb (blocking) and 10-4 M ranitidine before and 7 days after multiple bee 
stings. Bovine serum albumine, tetanus toxoid and bee venom allergen 
hyaluronidase were used as control Ags in non responsive donors. On day 6, cells 
were collected, stained with anti-CD4 PE, and analyzed by FACS (one 
representative of 3 beekeepers is shown). b) PBMC of three different beekeepers 
were stimulated with PLA and different doses of ranitidine or anti-IL-10 receptor mAb 
or both. [3H]-thymidine incorporation was determined at day 6. 
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Predominant Role of IL-10, but not TGF-β in Skin Related Tolerance.  
Neutralization experiments revealed that multiple suppressive mechanisms play a 
role in suppression of allergen-specific Th2 cells. IL-10 and TGF-β has been 
suggested to co-operate in suppression of mucosal allergen-specific T cell activation 
against mucosal antigens (87). It appeared that IL-10 plays a more dominant role 
than TGF-β in suppression of bee sting and skin related PLA-specific T cell 
responses (Fig. 16A). Blocking of IL-10, but not TGF-β binding to its receptor, 
reconstituted the suppressed specific T cell proliferation and cytokine production 
after bee stings. The suppressive effect of IL-10 was equal in both Th1 cytokine IFN-
γ and Th2 cytokine IL-13. In addition, two other mechanisms apparently function in 
immune tolerance to high dose venom allergens, because neutralization of either 
cytotoxic T lyphocyte-associated antigen (CTLA)-4 or programmed death (PD)-1 
significantly blocked the Tr1 cell-mediated suppression of T cell proliferation (Fig. 
16B). PLA-induced T cell proliferation was significantly high in PBMC of bee venom 
allergic donors. A suppression of T cell proliferation was achieved by increasing the 
frequency of PLA-specific IL-10-secreting T cells, which was partially inhibited by 
blocking of CTLA-4 or PD-1. 
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Figure 16. Multiple suppressive mechanisms play a role in peripheral allergen 
tolerance. a) Endogenous IL-10, TGF-β or both were neutralized in PLA-stimulated 
PBMC of beekeepers during bee keeping season. [3H]-thymidine incorporation 
(TdR), IFN-γ and IL-13 were determined at day 5. b) PLA-specific proliferation of 
PBMC from beekeepers before multiple bee stings is suppressed by 10 times 
increased frequency of PLA-specific IL-10-secreting T cells. The activity of CTLA-4 
and PD-1 were neutralized. [3H]-thymidine incorperation was determined at day 6 
(cells: no neutralizing Ab or isotype control antibody, IC: isotype control antibody). (a, 
b) Same results were obtained in six other independent experiments all performed 
with freshly purified cells without in vitro expansion (*: p<0.001). 
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Discussion 
The immune system must distinguish between innocuous and pathological antigens 
to prevent unnecessary and self-destructive immune responses (341). The human 
model we envisaged demonstrates how soluble protein antigens encountered via 
skin exposure are tolerated. Compared to aeroallergen exposure, the bee venom 
model is better controlled and represents a much higher dose of allergen inoculation 
via skin. Beekeepers received an average of 13 beestings in one week and they did 
not develop fever, draining lymph node swelling or splenomegaly. Induction of 
clinical tolerance parallel to immunological tolerance should be emphasized here, 
since these beekeepers showed local cutaneous late-phase reactions characterized 
by local swelling during the first few bee stings of every new season, which 
significantly diminished after one week. 
One of the key findings of the present study concerns the life span and allergen-
dependence of allergen-specific peripheral T cell tolerance. The cytokine profile of 
memory T cells specific for PLA show an IL-10- and IFN-γ-predominant profile out of 
the bee keeping season. Upon bee venom exposure, an immediate switch of 
allergen-specific T cells from Th1 and Th2 cells towards Tr1 cells occurs within a few 
days. These sequential events are repeated every year. At the end of every season 
when there is no exposure, peripheral T cell response returns to the same levels 
before exposure within 2 to 3 months. The changes in cytokine profile, T cell 
proliferation and cutaneous late-phase response show parallel changes, 
demonstrating that this T cell tolerance induced by an in vivo switch to Tr1-like IL-10-
secreting cells is short-lived and dependent on antigen exposure. There is so far no 
report on in vivo turnover and lifespan of Tr1 cells in humans, but our data is in 
agreement with the in vivo doubling time of FoxP3+CD25hiCD4+ T cells, which was 
demonstrated to be relatively short (8 days) in resting conditions compared to 
FoxP3-CD25-CD4+ T cells (24 days) (342). Interestingly, when bee venom contact 
ceased, the Tr1 response substantially decreased within maximum 2 months. 
Another essential data of the present study demonstrates in vivo clonal 
switch in allergen-specific IL-4-producing and IFN-γ-producing T cells towards IL-10-
producing T cells. The consistent profile of PLA-specific T cell proliferation in 
beekeepers throughout consecutive years demonstrates a biphasic T cell response 
with substantial peripheral T cell tolerance upon high dose allergen exposure. The 
long term PLA-specific T cell repertoire has been maintained by average balance of 
42% IFN-γ-secreting T cells, 43% IL-10-secreting T cells and 15 % IL-4 secreting T 
cells. Immediately, after bee stings the repertoire changed and consisted of 80% IL-
Results
 
 92 
10-secreting T cells, 14% IFN-γ-secreting T cells and 6% IL-4-secreting T cells. The 
stability of cytokine profiles in differentiated effector and memory T cell subsets in 
humans is not fully known and it has been demonstrated that lineage committed 
memory T cell subsets are responsive to cytokine signals of the opposing lineage 
(343,344). The frequency of single PLA-specific CD4+ Tr1 cells ranges between 1 in 
1'000 and 1 in 20'000 of the whole CD4+CD25+ Treg cells. PLA T-cell epitope 
restriction pattern varies considerably from patient to patient, and at least 4 epitopes 
have been demonstrated (237,345). PLA-specific T cells demonstrated a clonality 
throughout the whole season. In two types of experiments, which investigated their T 
cell receptor clonality by PCR and flow cytometry, an immediate skew to IL-10 
producing Tr1 type cells was in vivo observed. Similarly, IL-10-secreting allergen-
specific T cells represented the predominant subset and were present at significantly 
higher frequency than IL-4- and IFN-γ-secreting T cells in food and aeroallergen 
sensitized individuals, who did not develop an allergic response (87). 
Allergen-specific immunotherapy in humans has been used successfully to 
treat allergies by inducing responsive cells to secrete IL-10, and this is analogous to 
the studies of low-zone tolerance (346). The IL-10-producing CD4+ Tr1-cell 
population that is induced by T cell epitope peptide immunotherapy and whole 
allergen immunotherapy induces specific Tr1 cells. Tr1 cells specific for a variety of 
antigens arise in vivo, but may also differentiate from naive CD4+ T cells in the 
presence of IL-10 in vitro (108). The non-specific T cell suppressor activity of IL-10 
and TGF-β has been consistently reported in experiments with high amounts of 
exogenously added suppressor cytokines (222). However, the present study 
demonstrates that Tr1 cells display antigen-specific suppressor activity in very low 
numbers. Depending on their frequency, the first T cell that contacts the APC may 
be very decisive for inducing or suppressing the generation of a specific immune 
response. Accordingly, if the first T cell to contact APC is a Tr1 cell, it may silence or 
regulate the maturation of APC. IL-10 down-regulates the antigen-presenting 
capacity such as HLA-DR expression, co-stimulatory molecules and several 
cytokines in dendritic cells and monocytes/macrophages (109). Differentiation of a 
distinct dendritic cell subset in the presence of IL-10 has been demonstrated, which 
induces tolerance through the generation of Tr1 cells (347).  
Allergen-specific T cell tolerance utilizes multiple suppressor mechanisms. 
CD4+CD25+ T cells are the only lymphocyte subpopulation in both mice and humans 
that express CTLA-4 constitutively. The expression apparently correlates with the 
suppressor function of CTLA-4. As demonstrated in the present study for Tr1 cells, 
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the blocking of CTLA-4 activity reverses suppression in co-cultures of CD4+CD25+ 
and CD4+CD25- T cells (105). Similarly, the treatment of mice, which are recipients 
of CD4+CD45RBlow T cells with CTLA-4-blocking agents abrogated the suppression 
of inflammatory bowel disease (348). These studies indicate that the engagement of 
CTLA-4 on the CD4+CD25+ T cells by antibody or by CD80/CD86 might lead to 
inhibition of the TCR-derived signals that are required for the induction of suppressor 
activity. PD-1 is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing 
receptor expressed upon T cell activation. PD-1-deleted mice develop autoimmune 
diseases, suggesting an inhibitory role for PD-1 in immune responses (106). 
Members of the B7 family, PD-ligand (L) 1 and PD-L2, are ligands for PD-1. PD-
1/PD-L engagement on murine CD4 and CD8 T cells results in inhibition of 
proliferation and cytokine production. T cells stimulated with anti-CD3/PD-L1Fc-
coated beads display dramatically decreased proliferation and IL-2 production (107).  
The present study demonstrates that HR2 represents an essential receptor that 
participates in peripheral tolerance to allergens by induction of IL-10 and directly 
suppression of the proliferation of allergen-specific T cells. Differential patterns of HR 
expression on Th1 and Th2 cells determine reciprocal T cell responses following 
histamine stimulation. Human CD4+ Th1 cells predominantly express HR1 and CD4+ 
Th2 cells HR2, which results in their differential regulation by histamine (92). 
Histamine enhances Th1-type responses by triggering the HR1, whereas both Th1- 
and Th2-type responses are negatively regulated by histamine binding to HR2 (92). 
Histamine induces the production of IL-10 by DC (89), and enhances the 
suppressive activity of TGF-β on T cells (91). In the differentiation process of 
monocyte-derived dendritic cells, HR2 acts as a suppressive molecule for antigen-
presentation capacity, suppresses IL-12 production and enhances IL-10 production 
(89,287). All of these immune tolerance promoting effects are mediated via HR2, 
which is relatively highly expressed on Th2 cells and suppresses IL-4 and IL-13 
production and T cell proliferation (92).  
Studies on T cell response to allergens in healthy individuals have 
demonstrated a wide range of immune response from no detectable response to 
involvement of active peripheral tolerance mechanisms (312). In a high number of 
healthy individuals, T cells do not show any proliferative response to allergens in 
PBMC cultures, which can be due to low frequency of specific T cells, due to lack of 
exposure or exposure below the threshold of sensitization dose. Active suppression 
against allergens by Treg cells occurs in sensitized healthy individuals (87,224). In 
individuals, who show a detectable IgG4 response, a balanced allergen-specific 
immune response due to expansion of Tr1 cells has been demonstrated (87). 
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Collectively our results indicate that the control of Th2 and Th1 immune responses 
against naturally exposed harmless environmental antigens is mediated by Tr1 cells 
in humans. Effector (allergen-specific Th2) and suppressor (allergen-specific Tr1) T 
cells exist in both healthy and allergic individuals in certain amounts. Their ratio 
determines the development of a healthy or an allergic immune response. These 
data may explain the spontaneous development and spontaneous remission of 
allergic diseases. In addition to allergy, these mechanisms may have implications in 
autoimmunity, graft-versus-host disease, tumor cell growth, parasite survival and 
chronic infections.  
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Material and Methods 
Study population and allergens. 10 beekeeper volunteers (mean age: 58 y, range 
34-71 y, 9 male, 1 female, average bee keeping time 36 y; range 17-46 y) who 
reported that they do not use protection equipment and show cutaneous late-phase 
swelling response to bee stings in the beginning of each season. Physical 
examination and questionnaires have been performed, and heparinized peripheral 
venous blood samples have been taken. Recombinant phospholipase A2 (PLA) and 
hyaluronidase (HYA) of honey bee venom (Apis mellifera), Bet v 1 of birch pollen 
(Betula verrucosa), rDer p 1 of house dust mite (Dermatophagoides pteronyssinus) 
were used. Purified protein derivative of mycobacterium bovis (PPD) and tetanus 
toxoid (TT) were used as control antigens. All of the allergens did not contain 
detectable amounts of LPS and were >99% pure.  
 
Purification of allergen-specific IL-4-, IFN-γ- and IL-10-secreting cells. PBMC 
were isolated by Ficoll (Biochrom, Berlin, Germany) density gradient centrifugation of 
peripheral venous blood and cells were washed three times and resuspended in 
RPMI 1640 medium supplemented as described (87). 2.5x107 cells were stimulated 
with 0.3 µM antigens in 5 ml medium in 6-well plates in duplicates (Costar Corp., 
Cambridge, MA, USA). After 12 h of stimulation in humidified 5% CO2, cells were 
harvested and labeled with 50 µg/ml of anti-IFN-γ/CD45, anti-IL-4/CD45 or anti-IL-
10/CD45 Ab-Ab conjugates (Miltenyi Biotec, Bergish, Gladbach, Germany) for 10 
min at a concentration of 108 cells/ml in ice cold RPMI 1640 medium (349). The cells 
were diluted with 37°C warm medium to a final concentration of 106 cell/ml and 
allowed to secrete and capture the respective cytokines for 45 min at 37°C. After 
capturing the secreted cytokines on their surface, cells were centrifuged at 300xg for 
5 min at 4°C and resuspended at a concentration of 108 cells/ml in ice cold buffer 
containing 0.5% BSA and 5 mM EDTA (both from Sigma Chem. Co. St. Louis, MA) 
in PBS. The cells were then stained with 5 µg/ml PE-conjugated anti-IFN-γ, anti-IL-
10 or anti-IL-4 for 10 min, at 4°C. Then, the cells were washed and resuspended in 
BSA-EDTA PBS (108 cells/ml) and magnetically labeled for 15 min at 4°C with 20 ml 
per 107 cells of anti-PE microbeads. After washing, labeled cells were purified by 
immunomagnetic separation (AutoMacs, Miltenyi Biotec, Bergish, Germany). The 
cells were counter-stained by FITC labeled anti-CD4 mAb (Immunotech, Marseilles, 
France) and analyzed in a flow cytometer (Epics XL, Coulter Corp. Hialeah, FL, 
USA) and their percentage in whole CD4+ T cells and frequency was calculated. 
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Together with the quantitative cytokine mRNA and secreted cytokine profiles these 
data demonstrate that antigen-specific Tr1, Th1 and Th2 cells can be purified from 
human peripheral blood (Supplementary Fig. 6) and they are specific for the allergen 
that they are initially stimulated for the purification (Supplementary Fig. 7). The purity 
of allergen-specific CD4+ cytokine-secreting cells was between 88-96%. The 
frequency of allergen stimulated and unstimulated cells was calculated by dividing 
the number of purified cytokine-secreting CD4+ T cells by the initial number of CD4+ 
T cells (Supplementary method). 
 
T cell cultures. Allergen-specific cytokine-secreting T cells were used immediately 
after purification in all experiments. Allergen-specific T cell proliferative response 
was determined by stimulation of 2 x 105 PBMC alone or together with freshly 
purified allergen-specific cytokine-secreting T cells for 5 days with 0.3 µM allergens, 
1 µg/ml tetanus toxoid and PPD in 200 ml medium in 96-well flat-bottom tissue 
culture plates in triplicates (123). Autologous 3000 rad irradiated PBMC were used 
as APC. Cells were pulsed with 1 mCi/well [3H] thymidine (Du Pont / New England 
Nuclear, Boston MA) and incorporation of labeled nucleotide was determined after 8 
h in a LKB beta plate reader (Wallax, Pharmacia Turku, Finland). Cell proliferation is 
additionally measured by carboxyfluoresceinsuccinimidyl ester (CFSE) labeling. 
Cells are labeled with CFSE (5 mM, Molecular Probes Europe, BV, Leiden, The 
Netherlands) and washed twice with medium before being subjected to the PLA 
stimulation. After 5 days, CD4+ cells are counter stained with Pc5-labelled anti-CD4 
and ECD-labelled anti-CD3 mAbs (BD PharMingen AG) and analysed by flow 
cytometry. 
IL-10 was neutralized in cultures with 4 mg/ml anti-IL-10R mAb (DNAX 
Research Institute, Palo Alto, CA) (350). TGF-β was neutralized in cultures with 100 
ng/ml recombinant human soluble TGF-β receptor II/Fc chimeric protein (R&D 
Systems, Wiesbaden, Germany) (222). Programmed death-1 (PD-1) activity was 
neutralized in cultures with 5 mg/ml anti-human PD-1 (Bioscience Insight 
Biotechnology Limited, Wembley, UK). Cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
activity was neutralized with 5 mg/ml anti-CD152 F (ab)2 (Ancell, Alexis Corporation, 
Lausen, Switzerland). The neutralizing activity of these approaches was controlled in 
titrated doses. Rabbit IgG, rat IgG, mouse IgG1 or bovine serum albumin (Coulter 
Corp.) served as control.  
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Flow cytometry and ELISPOT. PBMC of beekeepers before and 7 days after they 
received multiple bee stings were stimulated with PLA for 10 days. Intracellular 
cytokines were detected after anti-CD2, anti-CD3, and anti-CD28 mAb stimulation 
for 12 h. 2 mM monensin (Sigma Chem Co) was added during the last 10 h (98). 
The solid-phase sandwich ELISAs for IFN-γ, IL-4, IL-10 and IL-13 are performed in 
supernatants obtained at day 5 (98). 
106/ml PBMC from 6 healthy donors were stimulated in 200 µl medium, 96-
well flat bottom Enzyme-linked immunospot (ELISPOT) plates for 18 h (Euroclone 
Ltd., Milano, Italy). Locally produced IL-4, IFN-γ and IL-10 were captured by specific 
monoclonal antibodies. After cell lysis, trapped cytokine molecules were revealed by 
a secondary biotinylated detection antibody, which is recognised by streptavidin 
conjugated to alkaline phosphatase. Colored "purple" spots developed after 
substrate addition was determined (ImmunoSpot, Cellular Technology Ltd., 
Echterdingen, Germany). The number of spots determined in triplicates of 
unstimulated wells was subtracted from 0.3 µM PLA-stimulated wells. 18 h was 
found the optimal time for the determination of frequency of cytokine secreting cells, 
as it is the time point for highest cytokine secretion before T cell proliferation starts. 
 
Quantitative real-time PCR. Immediately after purification, antigen-specific 
cytokine-secreting T cells were lysed with RNeasy lysis buffer and the RNA was 
isolated using the RNeasy mini kit (Qiagen, Hamburg, Germany) and eluted in 30 µl 
ddH2O. Reverse transcription was performed with RevertAid M-MuLV Reverse 
Transcriptase, Random Hexamer Primers, dNTP Mix, Ribo Lock RNase Inhibitor (all 
from Fermentas Burlington, Canada). The PCR primers and probes were designed 
based on sequences reported in GenBank. Primers were: EF-1a forward primer 
5`CTG AAC CAT CCA GGC CAA AT 3`, EF-1a reverse primer 5`GCC GTG TGG 
CAA TCC AAT 3`, IL-13 forward primer A 5` GCC CTG GAA TCC CTG ATC A 3`, 
IL-13 reverse primer A 5` GCT CAG CAT CCT CTG GGT CTT 3`, IFN-γ forward 
primer B 5` TCT CGG AAA CGA TGA AAT ATA CAA GTT AT 3`, IFN-γ reverse 
primer B 5` GTA ACA GCC AAG AGA ACC CAA AA 3`, IL-10 forward primer 5`GGC 
GCT GTC ATC GAT TTC TT 3`, IL-10 reverse primer 5`TTG GAG CTT ATT AAA 
GGC ATT CTT C 3`, TGF-β1 forward primer 5`AAA TTG AGG GCT TTC GCC TTA 
3` and TGF-β1 reverse primer 5`GAA CCC GTT GAT GTC CAC TTG 3`, HR1 
forward primer: 5’-TCT CGA ACG GAC TCA GAT ACC A-3’, HR1 reverse primer: 5’-
CCT GTG TTA GAC CCA CTC CTC AA-3’, HR1 probe: FAM-ACA GAG ACA GCA 
CCA GGC AAA GGC AA-TAMRA; HR2 forward primer: 5’-GCT GGG CTA TGC 
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CAA CTC A-3’, HR2 reverse primer: 5’-GGT GCG GAA GTC TCT GTT CAG-3’, HR2 
probe: FAM-CCC TGA ACC CCA TCC TGT ATG CTG C-TAMRA; HR4 forward 
primer, 5’-GGG TCT TGA AGA TTG TTA CTC TGA TG-3’, HR4 reverse primer, 5’-
CTA GAA TCA TTG GCC CAT TCA CT-3’, HR4 probe: FAM-GCC AGC ACC CAA 
ACG GCC A-TAMRA; Foxp3 forward primer: 5’-CCC GGC CTT CCA CAG AA-3’, 
Foxp3 reverse primer: 5’-CAC CCG CAC AAA GCA CTT G-3’ (all were from 
Microsynth AG, Balgach, Switzerland). cDNAs were amplified using TaqMan® PCR 
mastermix (Applied Biosystems) according to the recommendations of the 
manufacturer in a total volume of 25µl in an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems). Relative quantification was performed as described 
(351). All amplifications were carried out in duplicates.  
 
TCR vb chain detection on CD4+ T cells. 7 x 106 expanded PLA-specific T-cells 
from beekeepers, stimulated either with PLA or anti-CD2/3/28 before and after 
multiple bee stings or PBMC of healthy donors were blocked for 10 min. at room 
temperature with mouse serum (Dako AG, Baar, Switzerland) and subsequent 
stained for 10 min. with anti-CD3-FITC (Clone UCHT1, IgG1 mouse, Beckman 
Coulter, Lyon, Switzerland) and anti-CD4-PC5 (Clone 13B8.2, IgG1 mouse, 
Beckman Coulter) or matching isotype controls. After washing the assay was split 
into 22 samples and stained for 15 min. with PE-labeled anti-TCR Vb 1, 2, 3, 5.1, 
5.2, 5.3, 7, 8, 9, 11, 12, 13.1, 13.6, 14, 16, 17, 18, 20, 21.3, 22, 23 mAbs or matching 
isotype controls (Beckman Coulter). The FACS measurement was performed on an 
Epics XL MCL (Beckman Coulter). 
 
TcR clonality analysis. DNA was isolated with the DNA micro kit (Qiagen, Hilden, 
Germany) and clonality was determined using the IdentiClone T Cell Receptor Beta 
Gene (TCRB) Clonality Assay (InVivoScribe Technologies, LLC, San Diego, CA, 
USA). This PCR based assay identifies clonal T cell receptor beta chain gene 
rearrangements. Multiple consensus DNA primers that target conserved genetic 
regions within the T cell receptor beta chain gene are used to detect these 
rearrangements. Specific primers in two assay tubes (A, B) target framework regions 
within the variable region and the joining region and the third assay tube targets the 
diversity and joining regions. The specimen control size ladder master mix targets 
multiple genes and generates a series of amplicons to ensure that the quality and 
quantity of the input DNA is sufficient for the test. The DNA was added to each of the 
four assay tubes together with AmpliTaq Gold DNA Polymerase (Applied 
Biosystems, Rotkreuz, Switzerland) and the DNA was amplified using a standard 
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program with a thermocycler (Eppendorf, Hamburg, Germany). A heteroduplex 
analysis was done to differentiate clonal and non-clonal PCR products. PCR 
products from tube A, B and C were denatured at 94°C for 5 minutes and 
immediately chilled at 4°C on an ice water bath for 60 min. This allows a re-
annealing of the clonal strands, which results in a single band within a polyclonal 
background on the gel. Normal or polyclonal DNA produces amplicons of different 
size, which results in a smear. PCR products were separated on 6% Novex TBE 
Polyacrylamide gels (Invitrogen, Carlsbad, CA, USA), stained with ethidium bromide 
then scanned and analysed using a FUJIFILM BioImager Analyzer FLA-3000 with 
BASReader software (Fuji Photo Film Ltd., Tokyo, Japan), and the AIDA software 
(Raytest, Straubenhardt, Germany). Polyclonal and clonal control DNA was used to 
monitor the performance of the assay.  
 
Statistical interpretation. Data are expressed as means + SEM. Wilcoxon Rank 
Sum test and Mann-Whitney U test were used for statistical analysis.  
 
Online supplemental material. Fig. S6 demonstrates that PLA-specific IL-4-, IFN-γ-
, and IL-10-secreting T cells represent Th2-, Th1- and Tr1-like cells, respectively. 
Fig. S7 shows the antigen-specificity of purified cytokine-secreting T cells as 
determined by stimulation with the allergen that was originally used for stimulation 
before purification, and several control antigens in the presence of autologous APC. 
Supplementary method explains how the frequency of purified allergen-specific T 
cells is calculated. 
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Online supplementary material 
 
 
Figure S6 
PLA-specific IL-4-, IFN-γ-, and IL-10-secreting T cells represent Th2-, Th1- and Tr1-
like cells, respectively  
CD4+ T cells specific to bee venom PLA were isolated according to their IL-4, IFN-γ 
and IL-10 secretion profile. To confirm their cytokine profile, mRNA of IL-10, IL-13, 
IFN-γ and TGF-β were quantified immediately after isolation (Fig. S6A). Relative to 
the housekeeping gene EF-1α, IL-10-secreting T cells expressed significantly high 
IL-10 mRNA and IFN-γ-secreting T cells expressed significantly high IFN-γ mRNA. 
IL-13 mRNA was dominant in IL-4-secreting T cells. Same results were obtained in 
three independent experiments. 
Purified allergen-specific cytokine-secreting T cells were expanded for 2 
weeks in the presence of 1 nM doses of growth factors (IL-2 for IFN-γ-secreting T 
cells, IL-2 and IL-4 for IL-4-secreting T cells, IL-2 and IL-15 for IL-10-secreting T 
cells) (Novartis, Basel Switzerland). Quantification of their cytokine profile in 
supernatants by ELISA 72 hours after anti-CD3 and anti-CD28 mAb stimulation 
demonstrated that these subsets contain Th2-like (IL-4 and IL-13 high), Th1-like 
(IFN-γ high) and Tr1-like (IL-10 high) cells, respectively (all P <0.0001 compared to 
other subsets) (Fig. S6B). In addition, all three purified subsets consisted of some 
Th0 cells, which secrete both Th1 and Th2 cytokines as well as IL-10 and TGF-β. 
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Figure S7 
Antigen-Specificity of Purified Cytokine-Secreting T Cells 
The antigen-specificity of purified cytokine-secreting T cells was determined by 
stimulation with the allergen that was originally used for stimulation before 
purification, and several control antigens in the presence of autologous APC. T cells 
purified by certain antigen stimulation did not show any cross-reactivity against 
control antigens. All three subsets purified by bee venom PLA stimulation responded 
to PLA and whole bee venom, but not to HYA as another bee venom major allergen. 
[3H]-thymidine incorporation (TdR) was determined after 5 days. *:p<0.001. One 
representative of 3 different donors is shown. 
 
 
Supplementary Method 
Frequency calculation of purified allergen-specific T cells. The frequency of 
allergen stimulated and unstimulated cells was calculated by dividing the number of 
purified cytokine-secreting CD4+ T cells by the initial number of CD4+ T cells. To 
obtain the frequency of allergen-specific, cytokine-secreting T cells, the unstimulated 
cytokine-secreting CD4+ T cell frequency was subtracted from allergen-stimulated 
cell number. Cells were counted by using 9 mm2 area of a Neubauer counting 
chamber and trypan blue exclusion. The number of CD4+ cells was calculated as 
follows as an example of PLA-specific, IL-10-secreting CD4+ T cells. Allergen-
stimulated cells: 47.4 x 106 (cell count from culture after 12 h) x 52.8 % (percentage 
of CD4+ T cells) = 25.02 x 106 CD4+ T cells at the start. Unstimulated cells: 47.1 x 
106 (cell count from culture after 12 h) x 53.1 % (percentage of CD4+ T cells) = 25.01 
x 106 CD4+ T cells at the start.  Cells were counted and the number of purified CD4+ 
IL-10-secreting T cells was calculated as follows. PLA-stimulated cells: 33’000 (cell 
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count after purification) x 92.4 % (percentage of purified CD4+ IL-10+ T cells) = 
30’492 purified CD4+ PLA-specific, IL-10-secreting T cells. Unstimulated cells: 
11’000 (cell count after purification) x 88.4 % (percentage of purified CD4+ IL-10+ T 
cells) = 9’724 CD4+ and IL-10-secreting T cells without any stimulation. Cell 
frequency was calculated by dividing purified CD4+ IL-10-secreting T cell number by  
CD4+ T cell number at the start of cytokine secretion assay. PLA-stimulated cells: 
30’492 divided by 25.02 x 106 = 0.001218 (12.12 cells in 10’000). Unstimulated cells: 
9’742 divided by  25.01 x 106 = 0.000389 (3.89 cells in 10’000). Final frequency of 
PLA-specific IL-10-secreting T cells is calculated by subtracting unstimulated CD4+ 
IL-10-secreting cell frequency from PLA-specific CD4+ IL-10-secreting cell frequency 
(0.001218 - 0.000389 = 0.000829). That means, 8.29 cells in 10’000 CD4+ cells are 
PLA-specific, IL-10-secreting, Tr1-like cells. All of the frequency calculations shown 
in Figure 11A were performed as above. 
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6.3  Statement of contribution to publications 
 
For the publication titled „Distinct regulation of IgE, IgG4 and IgA by T regulatory 
cells and toll-like receptors“, I performed all the experiments, except the methodology 
of ELISPOT. 
  
For the publication titled „Clonal switch to IL-10-secreting type 1 T regulatory cells in 
high dose allergen exposure“ I contributed to the experiments depicted in figure 11A 
and 11B, 12, 13, 14A and 14B, and the supplementary figure 6.
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7 Discussion 
Allergic diseases result from the activation of the immune system and formation of 
IgE antibodies against normally innocuous environmental antigens. Th2 cells and 
their associated cytokines have been demonstrated to play a key role in the induction 
of IgE and in multiple other mechanisms of allergic inflammation. Alterations in the 
susceptible balance between allergen-specific Treg and Th2 cells is very pivotal in 
the development and also treatment of allergic diseases. During the last few years, 
there has been an increasing interest in discovering the effector mechanisms of Treg 
cells. Understanding such effects of Treg cells is important for the development of 
new therapeutical drugs to prevent and cure allergic diseases or autoimmune 
diseases. 
 
7.1  Regulatory T cells play a role in the induction of IgG4 
and suppression of IgE 
The aim of the present study was to investigate the role of different subsets of Treg 
cells and toll-like receptors (TLRs) on IgE, IgG4 and IgA production. We used healthy 
individuals, because we investigated regulation of Ig isotype switch and production in 
normal conditions. We showed that regulatory T cells not only influence Th1 or Th2 
cell responses, but that those cells also directly effect B cells. Freshly purified 
CD4+CD25+ Treg cells and IL-10-secreting Tr1 cells suppressed IgE and induced 
IgG4. Both regulatory T cell subsets also lowered IgE-secreting, and simultaneously 
augmented the IgG4-secreting plasma cell-frequency. In lymph nodes and tonsils, 
CD4+CD25+Foxp3+ Treg cells are present in B cell areas where T-B cell interaction 
and humoral immune responses occur, and can directly influence B cell Ig production 
and CSR without the requirement to suppress Th cells. This is supported by studies, 
which show decreased Treg cell function or number in several immune mediated 
diseases in humans and mouse models with increased autoantibody production 
(310,311) and it has also been shown that elimination of CD4+CD25+ Treg cells 
results in development of various autoimmune diseases. 
In healthy and allergic individuals, the Th1, Th2 and Tr1 type, allergen-
specific subsets are found in different proportions (87). Normally, the Tr1 cell subset 
specific for common environmental allergens is dominant in healthy individuals 
(87,312) and a change in the fine balance between Th2 and Treg cells can lead to 
either allergy development or recovery. CD4+CD25+ Treg cells have a frequency of 
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~10-15% of CD4+ T cells, while the incidence of Tr1 cells with a single allergen 
specificity is between 0.1 and 0.007% of CD4+ T cells. In other words, one allergen-
specific Tr1 cell can be found in 1'000 to 20'000 of the total CD4+ T cell population. 
But Tr1 cells are not anergic and they can differentiate from naive CD4+ T cells in the 
presence of IL-10 in vitro (108), and they have been shown to proliferate by IL-2, IL-
4, IL-7, and IL-15 (87). Although suppression by Tr1 cells is antigen-specific, high 
numbers of Tr1 cells (at least 20'000 in 100'000 PBMCs) result in a non-specific 
suppressive activity on anti-CD3-stimulated T cells.  
However, not only the ratio of different T cell subsets affects the outcome of 
an immune response, but also the ratio of certain antibody isotypes plays a very 
important role. Normally, allergic individuals have high levels of IgE and low amounts 
of IgG4 against a specific allergen. IgG4 has a low potential for inducing 
inflammation, because the IgG half-molecules can separate and pair again among 
IgG4, which leads to bi-specific antibodies that can not form large immune 
complexes (44,45). However, significant amounts of bispecific antibodies can be 
found only when two antigens, which induce high levels of IgG4 antibodies, are 
present at the same time in the body. Unless both antigens are present, the 
exchange process renders IgG4 antibodies monovalent (45). Furthermore, IgG4 is 
not able to activate the complement. In an allergen-specific immunotherapy study, in 
which well-defined recombinant allergen mixtures were used, all treated patients 
developed very strong allergen-specific IgG4 and also increased IgG1 antibody 
responses. Some patients, who were not initially sensitized to the major timothy 
grass pollen allergen Phl p 5 (Phleum pratense), developed strong specific IgG4, but 
not IgE antibody responses to that allergen (317).  
Allergen-specific IgG4 may be directed against the same epitopes as IgE, 
resulting in direct competition for allergen binding and a “blocking” effect. 
Approximately after 3 months of SIT, IgG4 antibodies reach sufficiently high levels or 
affinities to compete with the binding of IgE to allergens (217), and therefore, not only 
IgE-mediated allergen presentation to CD4+ T cells is prevented, but also histamine 
release from mast cells and basophils might be inhibited since the allergen is 
captured before reaching the effector cell-bound IgE (352). Kepley et al. showed that 
this reduced histamine release could be caused by a direct inhibition of the allergen-
IgE interaction or by coaggregation of the inhibitory FcγRIIB and FcεRI (353). 
Until recently, mast cells were thought to be the most important target cell that 
needed protection from IgE-mediated allergen triggering. However, the enormous 
potential of allergen-specific IgE antibodies in allergen presentation to T cells must 
also be taken into consideration (217,354,355). Therefore, competition among IgE 
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and IgG4 at the level of antigen-presenting cell and the induction of IgG4 during SIT 
also dampens the T-cell dependent late-phase allergic reaction. Through inhibition of 
IgE-mediated allergen presentation, involvement of B cells as APC is reduced and 
the threshold for the activation of allergen-specific Th2 cells is enhanced. T cells are 
therefore activated through the presentation of the allergen by professional APCs 
such as DCs or macrophages, which requires higher allergen concentrations, 
favoring a Th1 response (356). During SIT, additional treatment with anti-IgE 
prevents the IgE-mediated allergen presentation and changes the sensitivity of the 
immune system for the allergens (357,358). 
IL-10 is a potent suppressor of both total and allergen-specific IgE, while it 
simultaneously increases IgG4 production (129). Thus, IL-10 not only generates 
tolerance in T cells, it also regulates specific isotype formation and skews the specific 
response from an IgE to an IgG4 dominated phenotype. The healthy immune 
response to Der p 1 demonstrated increased specific IgA and IgG4, small amounts of 
IgG1 and almost undetectable IgE antibodies in serum (222). House dust mite-SIT 
did not significantly change specific IgE levels after 70 days of treatment, however, a 
significant increase in specific IgA, IgG1 and IgG4 was observed (222). Most 
probably the decrease in IgE/IgG4 ratio during allergen-SIT is a feature of skewing 
an allergen-specific Th2 to a Treg cell predominance. However, although Treg cell 
generation happens within days, a significant decrease in IgE/IgG4 ratio occurs after 
several months. The reason for the long-time gap between the change in T cell 
subsets, but not IgE/IgG4 levels is not easily explainable by the half-life of antibodies. 
In this context, the role of bone marrow-residing IgE-producing plasma cells with very 
long lifespan remains to be investigated (318). It has also been suggested that rather 
affinity and epitope specificities of the induced IgG4 than the concentration should be 
analysed, since these features might be more relevant for the clinical effect of the 
antibodies (359). 
In patients allergic to bee venom, intramuscular or intravenous application of 
plasma from hyperimmune beekeepers with high levels of specific IgG showed a 
beneficial effect in a following allergen exposure (360,361). Passive administration of 
polyclonal human allergen-specific IgG could be a new way of treating allergy, 
however, it will probably not be as effective as SIT, because induction of an altered 
cytokine profile in T cells can not be realised. But, since IgG antibodies have a long 
half-life, two to three injections could be enough to obtain a protective effect during 
one pollen season. 
If the mechanism by which regulatory T cells act on B cells consists of 
physical cell-to-cell contact via ICAM-1, cell surface-bound TGF-β (130), CTLA-4 
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(322), GITR (323), PD-1 (324) and OX40 (CD134) (325), or, as very recently shown, 
via cyclic adenosine monophosphate and gap junctions (326), or if it is more an 
autocrine mechanism with IL-10 and TGF-β as soluble mediators, is not known yet. It 
appears however, that this antibody isotype regulation is partially dependent on IL-10 
as demonstrated in our inhibition experiments with anti-IL-10 and anti-IL-10 receptor-
antibodies and the transwell experiments. 
 
 
Figure 17. Antigen-presenting, IL-4 producing DCs prime naive T cells to differentiate 
to Th2 cells, which produce high amounts of IL-4 and IL-13. Those Th2 cytokines 
induce antibody isotype switching to IgE and IgG4 antibodies in naive B cells. IgG4 
plays an important role in neutralizing antigens, while IgE binds to FcεRI on mast 
cells and basophils. Antigen-binding and cross-linking of FcεRI leads to mast cell and 
basophil degranulation and release of vasoactive amins, lipid mediators, cytokines 
and chemokines, which subsequently elicit inflammatory effector responses. One 
task of both, Tr1 cells and CD4+CD25+ Treg cells is to induce the non-inflammatory 
IgG4 antibodies, but to suppress isotype switch to and production of inflammatory 
IgE antibodies. 
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7.2  IgA production is regulated by the innate immune system 
Furthermore, we demonstrated that direct TLR7 or TLR9 stimulation on B cells plays 
an important role for enhancing IgA production, while induction of IgA by Treg cells is 
very limited. This is a crucial finding in human Ig isotype regulation. In our 
experiments, IgA production is neither influenced by IL-10 nor by IL-10-secreting Tr1 
cells nor by CD4+CD25+ Treg cells. This antibody isotype is particularly regulated by 
activation of the innate immune system. Addition of TLR7 or 9 agonists to PBMC 
cultures highly upregulated IgA production and secretion, whereas T cell-help to B 
cells seems not to be necessary, since Tr1 cells and CD4+CD25+ Treg cells did not 
have any effect on IgA production. Recent evidence indicates that TLR stimulation on 
B cells can control immunoglobulin isotype switch. In mice, TLR9 and MyD88 are 
required for class switching to the pathogenetic IgG2a and IgG2b isotypes, but not 
for the development of IgM autoantibodies (186). Furthermore, CpG, but not LPS, 
upregulates T-bet expression in B cells and induces IgG2a, whereas it decreases 
IgG1 and IgE production (187,188). In humans, IL-10 upregulates TLR9 expression 
in B cells and TLR9 stimulation by CpG-DNA, in association with IL-10, initiates 
germline immunoglobulin heavy chain constant region Cγ1, Cγ2 and Cγ3 gene 
transcription, but not Cγ4 or Cε, and Cα has not been measured (190). Besides 
having a direct effect on B cells, TLR agonists can affect B cell differentiation and 
isotype switch indirectly through activation of DCs and subsequent release of IFN-α 
and IL-6 (191). Recently, it has been shown in mice and human, that gut DCs induce 
IgA class switch by synergistic effects of retinoic acid, IL-6 and IL-5 (195), however, 
the role of TLRs in DC mediated IgA induction remains to be elucidated. 
Interestingly, Lanzavecchia et al. suggest that extensive B cell proliferation, isotype 
switch and differentiation to Ig-secreting plasma cells require three signals: BCR 
triggering, T cell help and TLR stimulation (184). Zinkernagel et al. showed, that in 
mice, intestinal secretory IgA is produced by a T cell-independent and follicular 
organized lymphoid tissue-independent B cell subpopulation and derived largely from 
B1 peritoneal cells. This IgA production required the presence of the intestinal 
microflora and is therefore antigen-driven and does not simply reflect the presence of 
natural antibodies (177). 
To increase the efficacy of allergen-SIT, usage of TLR7/9 triggering 
substances as an adjuvant together with recombinant proteins may have a beneficial 
effect in allergen-specific immunotherapy. In this way, the blocking antibody isotype 
IgA is expected to increase simultaneously and support or even synergize the 
advantageous effects of IgG4 (218,319). Furthermore, CpG ODN used as adjuvants 
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for SIT, have been shown to skew the pathogenic Th2 immune profile towards a Th1 
profile (362). In another study, IFN-α-, IFN-γ-, LPS- or CD40L-stimulated human DCs 
up-regulated BAFF and APRIL, which induced together with IL-4, IL-10 or TGF-β 
CD40-independent class-switch recombination to Cγ, Cα or Cε in IgD+ B cells (192). 
In addition, TLR ligands and APRIL were shown to synergize to further enhance IgA2 
class switching (320). Moreover, it has been demonstrated that inducible-nitric-oxide-
synthase (iNOS) induces TGF-βRII on B cells and controls T-cell-dependent IgA 
class-switch recombination. Mucosa-associated lymphoid tissue (MALT) DCs 
express iNOS in response to the recognition of commensal bacteria by TLRs, which 
in turn leads to the production of BAFF and APRIL and subsequent T-cell-
independent IgA class-switch recombination in B1 cells (321). In the present study, 
we showed that stimulation of TLR7 and 9 highly induced total IgA in healthy 
individuals. It seems that IgA production is strongly dependent on the innate immune 
system. 
 
7.3  Induction of peripheral tolerance depends on a clonal 
switch towards IL-10-secreting Tr1 cells 
Discrimination between harmless and pathological antigens to prevent unnecessary 
and self-destructive immune responses is one of the most demanding task of the 
immune system (341,363). To get more insight into the mechanisms of the induction 
of peripheral tolerance, we used beekeepers as a human model to examine how high 
amounts of soluble protein antigens, which enter the body subcoutaneously via bee-
stings, are tolerated. The cytokine profile of PLA-specific memory T cells show an IL-
10 and IFN-γ predominant profile together with barely detectable IL-4 and IL-13 
beyond the beekeeping season. Upon bee venom exposure, an immediate switch of 
allergen-specific T cells from Th1 and Th2 towards Tr1 cells can be observed within 
a few days and, very interestingly, these sequential events are repeated every year. 
At the end of every beekeeping season when there is no exposure to the allergen 
anymore, peripheral T cell response returns within 2 to 3 months to the same levels 
as before exposure. The simoultaneous changes in cutaneous late-phase response, 
T cell proliferation and the cytokine profile suggest that T cell tolerance induced by 
an in vivo switch to Tr1-like IL-10-secreting cells is short-lived and dependent on 
antigen exposure. There is so far no report about in vivo turnover and lifespan of Tr1 
cells in humans, but our data are in agreement with the in vivo doubling time of 
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FoxP3+CD25hiCD4+ T cells, which was demonstrated to be relatively short (8 days) in 
resting conditions compared to FoxP3-CD25-CD4+ T cells (24 days) (342).  
Another major finding of the beekeeper study shows in vivo clonal switch of 
allergen-specific IL-4-producing and IFN-γ-producing T cells towards IL-10-producing 
T cells. PLA-specific T cells are able to proliferate persistently throughout 
consecutive years in beekeepers demonstrating a biphasic T cell response with 
substantial peripheral T cell tolerance upon high dose allergen exposure. The long 
term PLA-specific T cell repertoire has been maintained by an average of 42% IFN-γ-
secreting T cells, 43% IL-10-secreting T cells and 15 % IL-4-secreting T cells. 
Immediately, after receiving bee-stings, the repertoire changed and consisted of 80% 
IL-10-secreting T cells, 14% IFN-γ-secreting T cells and 6% IL-4-secreting T cells. 
The mechanisms underlying maintenance of cytokine profiles in differentiated 
effector and memory T cell subsets in humans is still not fully known. It has been 
demonstrated that human T cells exhibit plasticity in the differentiation program. 
Lineage-committed effector T cells and antigen-specific central memory T cells keep 
their ability to change their cytokine and chemokine receptor profiles in response to 
the expression of opposing transcription factors (343,344).  
PLA T-cell epitope restriction pattern is different in each individual, and at 
least 4 epitopes have been demonstrated to bind efficiently to human leukocyte 
antigens (HLA) II (237,345). In the beekeepers, PLA-specific T cells demonstrated 
clonality throughout the whole beekeeping season. We investigated their TCR 
clonality by PCR and flow cytometry, and could observe an immediate skew to IL-10-
producing Tr1 type cells in vivo. In individuals who were sensitized to food and 
aeroallergens and did not develop an allergic response, IL-10-secreting allergen-
specific T cells represented the predominant subset compared to IL-4- and IFN-γ-
secreting T cells (87). 
 In many studies, high amounts of exogenously added IL-10 and TGF-β 
provoked non-specific T cell suppressor activity (222). In the present study however, 
we showed that Tr1 cells display antigen-specific suppressor activity in very low 
numbers. Depending on their frequency, the first T cell that contacts the APC may be 
very decisive for inducing or suppressing the generation of a specific immune 
response. In the case of a Tr1 cell, the maturation of the APC may be arrested, since 
IL-10 down-regulates the antigen-presenting capacity such as HLA-DR expression, 
co-stimulatory molecules and several cytokines in DCs and monocytes/macrophages 
(109). Differentiation of a CD11clowCD45RBhigh DC subset in the presence of IL-10 
has been demonstrated, which induces tolerance by generating Tr1 cells (347).  
Discussion
 
 112 
It is still not clearly known which suppressor mechanisms allergen-specific 
Treg cells use to induce tolerance. CTLA-4 has been shown to be constitutively and 
specifically expressed on both human and mice CD4+CD25+ T cells, and the 
expression apparently correlates with the suppressor function of CTLA-4. The 
present and also previous studies demonstrated that blocking of CTLA-4 reverses 
the suppressor capacity of Tr1 and CD4+CD25+ T cells (105). Transfer of 
CD4+CD45lowCD25+ into mice with colitis and subsequent treatment with CTLA-4-
blocking agents reduced the suppression of the disease (348). These studies 
indicate that the engagement of CTLA-4 on the CD4+CD25+ T cells by antibody or by 
CD80/CD86 might lead to inhibition of the TCR-derived signals that are required for 
the induction of suppressor activity. We also found that PD-1, which is an 
immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor expressed 
upon T cell activation, seems to play an important role in the induction of tolerance. 
PD-1-deleted mice develop autoimmune diseases, suggesting an inhibitory role for 
PD-1 in immune responses (106).   
Another major finding of the present study is that HR2 represents a further 
essential receptor that participates in peripheral tolerance to allergens. We 
investigated the regulation of HRs on allergen-specific T cells and HR2 showed a 
significant increase exclusively in allergen/PLA-stimulated (IL-4-secreting) Th2 cells 
during the beekeeping season. Furthermore, histamine upregulated IL-10 production 
in Th2 cells via HR2 triggering and thereby converted them into Tr1 cells. 
Subsequently, the allergen/PLA-specific proliferation of CD3+CD4+ T cells was 
significantly reduced and could be reversed by addition of anti-IL-10R blocking 
antibody or ranitidine, a HR2 antagonist.  
Most PBMC cultures from healthy individuals do not show any T cell 
proliferative response to allergens. Reasons for that could be low frequency of 
specific T cells, lack of exposure or exposure below the threshold of sensitization 
dose. In sensitized healthy individuals, active suppression against allergens by Treg 
cells occurs (87,224). In individuals, who show a detectable IgG4 response, a 
balanced allergen-specific immune response due to expansion of Tr1 cells has been 
demonstrated (87). We suggest that Th2 and Th1 immune responses against 
naturally exposed harmless environmental antigens are controlled by Tr1 cells in 
humans. Effector (allergen-specific Th2) and suppressor (allergen-specific Tr1) T 
cells exist in both healthy and allergic individuals in certain amounts. Their ratio 
determines the development of a healthy or an allergic immune response. Our data 
may explain the spontaneous development and spontaneous remission of allergic 
diseases. In addition to allergy, these mechanisms may have implications in 
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autoimmunity, graft-versus-host disease, tumor cell growth, parasite survival and 
chronic infections.  
 
7.4  Conclusion and outlook 
We conclude that peripheral tolerance utilizes multiple mechanisms to suppress 
allergic inflammation. Apparently, Treg cells contribute to the control of allergen-
specific immune responses in several ways: I) Suppression of antigen-presenting 
cells that support the generation of effector Th2 and Th1 cells; II) Suppression of Th2 
and Th1 cells; III) Suppression of mast cells, basophils and eosinophils; IV) 
Interaction with resident tissue cells and remodeling (88). In addition to the above 
mechanisms, the present study demonstrates suppression of the inflammatory 
antibody isotype IgE and induction of the non-inflammatory antibody isotype IgG4 by 
Tr1 and CD4+CD25+ Treg cells. Furthermore, we got new insights into the lifespan 
and allergen-dependence of allergen-specific peripheral T cell tolerance, as well as 
clonal switch of allergen-specific IL-4-producing and IFN-γ-producing T cells towards 
IL-10-producing Tr1 cells. Besides IL-10 and TGF-β, Tr1 cells seem to require CTLA-
4 and PD-1 for suppressing antigen-specific T cell proliferation. And finally, after high 
dose allergen exposure, HR2 is highly upregulated and plays a further pivotal role in 
the induction of peripheral tolerance. 
The clinical relevance of Treg cells is of great interest. Generation of Treg 
cells or the increase of their suppressive capacity by drugs, cytokines or 
costimulatory molecules is an important target not only for the application in allergy 
and asthma, but also for transplantation and autoimmunity. However, it must be 
considered that Treg cells are not always responsible for a healthy immune 
response, since they can also induce chronicity of infections and tumor tolerance. 
Cellular therapy with antigen-specific Treg cells is another promising approach, since 
maintenance of long-term immune modulation and avoiding of general 
immunosuppression could be realized. 
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